JP4137998B2 - Powder coating composition for electrostatic coating of pharmaceutical substrates - Google Patents
Powder coating composition for electrostatic coating of pharmaceutical substrates Download PDFInfo
- Publication number
- JP4137998B2 JP4137998B2 JP53386596A JP53386596A JP4137998B2 JP 4137998 B2 JP4137998 B2 JP 4137998B2 JP 53386596 A JP53386596 A JP 53386596A JP 53386596 A JP53386596 A JP 53386596A JP 4137998 B2 JP4137998 B2 JP 4137998B2
- Authority
- JP
- Japan
- Prior art keywords
- powder
- substrate
- coating
- component
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000843 powder Substances 0.000 title claims abstract description 237
- 239000000758 substrate Substances 0.000 title claims abstract description 52
- 238000009503 electrostatic coating Methods 0.000 title claims description 16
- 239000008199 coating composition Substances 0.000 title 1
- 239000000463 material Substances 0.000 claims abstract description 255
- 238000000576 coating method Methods 0.000 claims abstract description 228
- 239000011248 coating agent Substances 0.000 claims abstract description 214
- 238000000034 method Methods 0.000 claims abstract description 77
- 239000011149 active material Substances 0.000 claims abstract description 36
- 239000011246 composite particle Substances 0.000 claims abstract description 32
- 238000009501 film coating Methods 0.000 claims abstract description 20
- 239000000126 substance Substances 0.000 claims abstract description 11
- 239000003826 tablet Substances 0.000 claims description 148
- 239000002245 particle Substances 0.000 claims description 132
- 239000010409 thin film Substances 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 29
- -1 polyoxyethylene Polymers 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 239000002202 Polyethylene glycol Substances 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 229920001223 polyethylene glycol Polymers 0.000 claims description 15
- 150000002148 esters Chemical class 0.000 claims description 14
- 229920001577 copolymer Polymers 0.000 claims description 13
- 229920002678 cellulose Polymers 0.000 claims description 12
- 239000007884 disintegrant Substances 0.000 claims description 12
- 239000001913 cellulose Substances 0.000 claims description 11
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 9
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 8
- 239000001993 wax Substances 0.000 claims description 8
- 239000002270 dispersing agent Substances 0.000 claims description 7
- 238000010422 painting Methods 0.000 claims description 7
- 239000003086 colorant Substances 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 229920001983 poloxamer Polymers 0.000 claims description 6
- 150000005846 sugar alcohols Chemical class 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 5
- 229940127557 pharmaceutical product Drugs 0.000 claims description 5
- 229920001290 polyvinyl ester Polymers 0.000 claims description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- 229920002732 Polyanhydride Polymers 0.000 claims description 4
- 229920000954 Polyglycolide Polymers 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 4
- 239000003605 opacifier Substances 0.000 claims description 4
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 4
- 229920000218 poly(hydroxyvalerate) Polymers 0.000 claims description 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 4
- 229920000098 polyolefin Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims description 3
- 239000002830 appetite depressant Substances 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 238000000184 acid digestion Methods 0.000 claims description 2
- 239000002269 analeptic agent Substances 0.000 claims description 2
- 230000000954 anitussive effect Effects 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000000567 anti-anemic effect Effects 0.000 claims description 2
- 239000004004 anti-anginal agent Substances 0.000 claims description 2
- 230000001142 anti-diarrhea Effects 0.000 claims description 2
- 230000003474 anti-emetic effect Effects 0.000 claims description 2
- 230000000843 anti-fungal effect Effects 0.000 claims description 2
- 230000002921 anti-spasmodic effect Effects 0.000 claims description 2
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 229940125714 antidiarrheal agent Drugs 0.000 claims description 2
- 239000003793 antidiarrheal agent Substances 0.000 claims description 2
- 239000002111 antiemetic agent Substances 0.000 claims description 2
- 229940121375 antifungal agent Drugs 0.000 claims description 2
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 229940127088 antihypertensive drug Drugs 0.000 claims description 2
- 239000003430 antimalarial agent Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000002221 antipyretic Substances 0.000 claims description 2
- 239000003434 antitussive agent Substances 0.000 claims description 2
- 229940124584 antitussives Drugs 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 239000002249 anxiolytic agent Substances 0.000 claims description 2
- 239000003613 bile acid Substances 0.000 claims description 2
- 229940124630 bronchodilator Drugs 0.000 claims description 2
- 239000000168 bronchodilator agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims description 2
- 239000003792 electrolyte Substances 0.000 claims description 2
- 229940037395 electrolytes Drugs 0.000 claims description 2
- 239000003172 expectorant agent Substances 0.000 claims description 2
- 230000003419 expectorant effect Effects 0.000 claims description 2
- 229940066493 expectorants Drugs 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000003527 fibrinolytic agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 230000002439 hemostatic effect Effects 0.000 claims description 2
- 230000000147 hypnotic effect Effects 0.000 claims description 2
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 229940124589 immunosuppressive drug Drugs 0.000 claims description 2
- 239000000411 inducer Substances 0.000 claims description 2
- 239000008141 laxative Substances 0.000 claims description 2
- 229940125722 laxative agent Drugs 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 229940066491 mucolytics Drugs 0.000 claims description 2
- 239000003158 myorelaxant agent Substances 0.000 claims description 2
- 230000002232 neuromuscular Effects 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 229940127234 oral contraceptive Drugs 0.000 claims description 2
- 239000003539 oral contraceptive agent Substances 0.000 claims description 2
- 239000002907 paramagnetic material Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 3
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000002460 anti-migrenic effect Effects 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 230000001754 anti-pyretic effect Effects 0.000 claims 1
- 230000002785 anti-thrombosis Effects 0.000 claims 1
- 239000000030 antiglaucoma agent Substances 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 230000003480 fibrinolytic effect Effects 0.000 claims 1
- 230000003345 hyperglycaemic effect Effects 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 239000007888 film coating Substances 0.000 abstract description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 24
- 238000002844 melting Methods 0.000 description 18
- 230000008018 melting Effects 0.000 description 18
- 239000007788 liquid Substances 0.000 description 14
- 239000000523 sample Substances 0.000 description 13
- 239000004408 titanium dioxide Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 238000012545 processing Methods 0.000 description 10
- 229910052782 aluminium Inorganic materials 0.000 description 9
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 9
- 239000003973 paint Substances 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000001816 cooling Methods 0.000 description 7
- 239000007921 spray Substances 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000005684 electric field Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000007373 indentation Methods 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 235000015067 sauces Nutrition 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960000878 docusate sodium Drugs 0.000 description 2
- 238000007610 electrostatic coating method Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- VILMUCRZVVVJCA-UHFFFAOYSA-M sodium glycolate Chemical compound [Na+].OCC([O-])=O VILMUCRZVVVJCA-UHFFFAOYSA-M 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000009492 tablet coating Methods 0.000 description 2
- 239000002700 tablet coating Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 229960005164 acesulfame Drugs 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940124433 antimigraine drug Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005674 electromagnetic induction Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- MJEMIOXXNCZZFK-UHFFFAOYSA-N ethylone Chemical compound CCNC(C)C(=O)C1=CC=C2OCOC2=C1 MJEMIOXXNCZZFK-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000004247 glycine and its sodium salt Substances 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 238000007591 painting process Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229940029258 sodium glycinate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- WUWHFEHKUQVYLF-UHFFFAOYSA-M sodium;2-aminoacetate Chemical compound [Na+].NCC([O-])=O WUWHFEHKUQVYLF-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940071117 starch glycolate Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/005—Coating of tablets or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B5/00—Electrostatic spraying apparatus; Spraying apparatus with means for charging the spray electrically; Apparatus for spraying liquids or other fluent materials by other electric means
- B05B5/08—Plant for applying liquids or other fluent materials to objects
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B5/00—Electrostatic spraying apparatus; Spraying apparatus with means for charging the spray electrically; Apparatus for spraying liquids or other fluent materials by other electric means
- B05B5/08—Plant for applying liquids or other fluent materials to objects
- B05B5/081—Plant for applying liquids or other fluent materials to objects specially adapted for treating particulate materials
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B5/00—Electrostatic spraying apparatus; Spraying apparatus with means for charging the spray electrically; Apparatus for spraying liquids or other fluent materials by other electric means
- B05B5/08—Plant for applying liquids or other fluent materials to objects
- B05B5/082—Plant for applying liquids or other fluent materials to objects characterised by means for supporting, holding or conveying the objects
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B5/00—Electrostatic spraying apparatus; Spraying apparatus with means for charging the spray electrically; Apparatus for spraying liquids or other fluent materials by other electric means
- B05B5/08—Plant for applying liquids or other fluent materials to objects
- B05B5/087—Arrangements of electrodes, e.g. of charging, shielding, collecting electrodes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D1/00—Processes for applying liquids or other fluent materials
- B05D1/02—Processes for applying liquids or other fluent materials performed by spraying
- B05D1/04—Processes for applying liquids or other fluent materials performed by spraying involving the use of an electrostatic field
- B05D1/045—Processes for applying liquids or other fluent materials performed by spraying involving the use of an electrostatic field on non-conductive substrates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Paints Or Removers (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Electrostatic Spraying Apparatus (AREA)
- Application Of Or Painting With Fluid Materials (AREA)
- Glanulating (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pretreatment Of Seeds And Plants (AREA)
Abstract
Description
本発明は、粉末塗装材料による医薬基材の静電塗装および医薬基材塗装用の粉末塗装材料に関するものである。特に、本発明は、粉末塗装材料による医薬錠剤芯の静電塗装および医薬錠剤芯塗装用の粉末塗装材料に関するものであるが、これに限定していない。明細書の全体にわたり医薬錠剤に言及し、且つ特に、本発明は従来形状の医薬錠剤に関する出願とみられがちであるが、この用語は、ペレット、カプセルや小球の如き経口摂取されるその他の製品も包含するような広範な意味で解釈すべきである。
金属物体のような導電性基材の静電塗装はよく知られるところである。例えば、ある種の塗料噴霧方法において、塗料を帯電させて、接地した金属物体上に塗料滴を噴霧する。この方法は、基材上に均一塗装膜を形成させる点で成功を収めている。
非電導性基材、特に医薬錠剤芯の静電塗装はかなり難しい。何年もの間、錠剤の静電塗装に関する提案が行われてきた。例えば、英国1075404号は錠剤塗装用の装置を提案しており、高ポテンシャル場で塗装溶液の微細粒子を噴霧器を用いて錠剤上に噴霧している。一例として赤外線ヒーターを用いて塗装を乾燥する。しかし、この提案は実質的に産業的な規模で実施されたことがなく、かつ医薬錠剤芯の塗装は、回転ドラム中で液体塗料を適用することにより、バッチ法で通常実施している。この液体塗装材料は、或る場合には勿論、粉末形態で供給されることもあるが、仮にそうであっても、その後に塗装材料は液体中に溶解または分散させて使用する。従って、塗装材料は粉末形態で錠剤芯に適用していない。
医薬錠剤芯に対して粉末塗装より液体塗装の適用が、多くの場合に容易である。錠剤に粉末を固着させることが難しく、且つ芯に塗装を固定するために、通常有機材料を含んでいる錠剤芯を傷めることなく、粉末を薄膜に変換する必要がある。さらに、均一塗装が要求され、錠剤芯上に均一な粉末塗装を得ることが難かしい。
液体塗装を使用する場合、塗装を乾燥する必要がある。理論上は、或る環境で乾燥を室温で実施可能であるが、しかしながら、工程を実施する速度の点から錠剤の加熱は産業の場では重要であり、且つ液体塗装に使用した溶剤を蒸発させるために必要なエネルギーの大量投入故に費用がかかる。液体塗装の他の欠点は、有用な液体、好適には水に溶解しない又は適切に分散しない材料は塗装材料に使用できない点である。
WO92/14451号は、医薬錠剤の静電粉末塗装に関するものであり、医薬錠剤芯を接地したコンベヤベルトにのせて移送し、静電的帯電粉末を芯に向けて噴霧して芯表面に固着した粉末塗装を形成させる方法を解説すると共に例証している。その後に、粉末塗料は溶融して芯に固定した溶融薄膜塗装を与える。
このような方法の欠点は、芯に向けて噴霧した粉末の大部分が帯電せず、芯上に沈積しないことである。このことは、噴霧飛沫と粉末材料の浪費に繋がり、且つ均一塗装の達成を困難にしている。
第1の観点では、本発明は、医薬錠剤芯の静電粉末塗装用に適した粉末塗装材料の提供を試み、且つ医薬錠剤芯の静電塗装方法を提供し、特殊粉末塗装材料の使用により静電塗装を容易にする試みを行う。
本発明の第1の観点は、錠剤芯の静電粉末塗装、特に以下に定義する塗装方法に用いるもので、且つこの方法に対する使用適性を与える特殊な特性を有する、粉末塗装材料を提供するものである。好ましくは、粉末塗装材料が有する前記の特殊な特性は以下に定義するもので、そしてこの特性により与えられる利点は採用する塗装方法の影響を受ける故、この方法もまた定義する。
本発明の第1の観点によれば、本発明は、医薬錠剤芯の静電粉末塗装に適する粉末塗装材料を提供するもので、前記材料は医薬的に許容でき、薄膜塗装加工ができ、且つ複合粒子を含み、前記複合粒子は異なった物理的及び/又は化学的特性を有する2またはそれ以上の成分から構成される。
粉末塗装材料が医薬的に許容できる材料であることは重要である。これは、それ自体が、粉末塗装材料に厳しい制約を課するもので、静電粉末塗装加工用として商業的に入手可能な少なくとも大部分の粉末塗装材料は生理学的に容認されず、且つ医薬錠剤芯の塗装材料として商業的に入手可能な材料は、その他の材料特性が不適切である理由により一般的に静電粉末塗装に向いていない。
本発明の粉末塗装材料は、少なくとも2種の異質な成分を含み、それぞれの異質な成分は異なる物理的及び/又は化学的特性を所有している。1成分材料の使用に比べ1成分以上から成る材料の使用により、前述のおよび明細書の何れかの箇所に記載する所望の特性を有する粉末材料の提供は、可なり容易になる。2またはそれ以上の異質な成分を含有する粉末材料に関して、粉末が数成分の複合粒子を含む場合に、改良塗装が達成されることを我々は見いだした。
用いる塗装方法が、例えば下記の実施例に記載されるような場合、1またはそれ以上の成分が芯上に塗装するために必要とする電気的特性を持たないならば、塗装材料粒子が1以上の成分を含有することは、特に重要となる。粒子が複合粒子でない場合、必要な電気的特性を有さない成分から成るこれらの粒子が、粉末供給源に単に止まることがあり、錠剤芯上に塗装されないであろう。
本明細書で使用する「複合粒子」の用語は、2またはそれ以上の異なる成分から形成される粒子を言う。この複合粒子は均質ではなく、複合粒子はそれぞれが異なる成分の微粒子から構成される2またはそれ以上の領域を有している。複合粒子は、個々別々の複合粒子形態であるか、或いは異なる成分の個々の粒子の集塊または凝集体であってもよく、集塊または凝集体は別々の複合粒子の挙動を示すものである。
有利な点として、少なくとも50重量%の粉末粒子が複合粒子である。理想的なことをいえば、実質的に全ての粒子が複合粒子であればよいが、これは、特に複合粒子の粒子サイズが小さい場合、成し得ないことである。粉末が異なる物理的及び/又は化学的特性を有する2以上の成分を含む場合、好都合には、この複合粒子はその他の成分も含んでいる。理想的には、実質的に全ての複合粒子が、異質な成分のそれぞれを含む個々に分離した粒子から構成されることである。しかしながら、実際には、個々の成分粒子が凝集体または集塊として複合粒子を形成する場合に、満足な塗装が得られている。
好ましくは、2またはそれ以上の成分が同時処理される。この同時処理は、造粒、噴霧凝固、噴霧乾燥または同時粉砕から構成される。この同時処理が比較的大きいサイズを、例えば顆粒を、生むような結果となる場合、或る場合には引き続いて粉砕工程を行い、粒子サイズを減少させることが好都合である。新たに、微小化工程を実施してもよい。
周知の如く、粉末成分の混合により、通常は成分の均一な混合物が得られる。しかしながら、特殊な場合、混合条件、例えば成分の初期粒子サイズと混合手段を注意深く選択することにより、混合方法により複合粒子を得ることができる。
本発明の第1の観点に従えば、粉末塗装材料は、該材料を錠剤芯表面に塗装した後、処理して芯に固定された薄膜塗装を形成可能な材料である。このように、本発明の塗装方法は、錠剤芯表面を粉末で塗装後粉末を処理し錠剤芯表面に固定された薄膜塗装を形成する工程を含むものである。薄膜塗装は連続していることが好都合であり、この場合塗装は別々の部分に分割されていないが、しかし例えば処理工程中に互いに固定された塗装粒子間に、肉眼で認識不能な小間隙が存在している。このように、塗装は焼結したものである。或る用途では、薄膜塗装に間隙が存在しないか及び/又は実質的に均質であることが好ましい。
錠剤芯に初めに沈積した粉末材料は、多くの場合基材表面に単に弱く接着しているだけで、容易に取り除ける。しばしば錠剤芯自体の機械的強度が小さい故、医薬錠剤芯に塗装を行う場合に、薄膜塗装を形成するための処理は特に有利であり、そして強度付与のために薄膜塗装が使用され、塗装錠剤を包装や包装開封の如き次工程に更に耐えられるようする。薄膜塗装は錠剤芯に特別な強度を付与できるが、芯表面から分離したときにはしばしば大変に弱いものである。遊離薄膜としての薄膜塗装の抗張力は、例えば8MNm-2またはそれ以下であり、そして塗装材料中のTiO2の量の増加に伴い抗張力が減少することが判明した。
遊離薄膜の抗張力が小さい場合、薄膜が、錠剤芯に対して優れた接着力をもち芯表面で凝集性の塗装となることが特に重要である。
粉末材料が薄膜塗装形成工程で液体相に変換される場合、該液体相中で粉末材料の粘度は500パスカル以下、より好適には75パスカル以下であることが好ましい。
粉末塗装材料が、薄膜塗装形成のために、250℃以下、より好適には200℃以下の温度で処理可能であることは利点である。好都合なことに、粉末塗装材料が、大気圧下で250℃以下、より好適には200℃以下の温度で溶融可能である。錠剤芯を傷めることなく粉末を処理して錠剤芯の周囲に塗装を形成することが重要であり、そしてこれは、有機材料を含有する多くの錠剤芯が熱に敏感である故、粉末材料に対し要求を課すことになる。粉末塗装材料は、好適には50℃〜180℃の範囲、より好適には60℃〜100℃の範囲の融点を有する。ガラス転移を示す材料では、粉末塗装材料は好適には30℃〜180℃の範囲の軟化点を有する。
上記の要件は粉末塗装材料に対し更なる制約を置くことになる。多くの材料は溶融せず、熱により炭化する。溶融性である他の材料と言えども、溶融のために熱源に長時間暴露する必要があり、それ故に芯に対し損傷を与える危険が相当に増大し、また芯上に薄膜を形成させる時間が経済的理由により容認しがたい。
粉末塗装材料が処理可能な所望温度は、当然のことながら錠剤芯を作成する材料により左右され、或る材料では処理工程が250℃を超える温度を含むこともあり得る。このような場合、そのような高温度への暴露時間は短縮される。
好ましくは、薄膜塗装を形成する粉末処理は、加熱工程、好適には赤外線輻射を用いた加熱工程を含み、しかも他の形態として電磁放射、電磁伝導、または電磁誘導を使用できる。粉末材料の処理は錠剤芯の周囲の圧力を部分的または全体に減圧して行うことができる。処理中の粉末材料の変化は、固体から液体へ、そして冷却により連続的固体薄膜への単純な物理的変化である。最近では、粉末材料は、処理中に硬化できるポリマー、例えばγ線、紫外線または無線周波帯のエネルギー照射により硬化して架橋ポリマー薄膜を形成するポリマーを含むことができる。
粉末塗装材料の粒子サイズが、静電粉末塗装法における材料の挙動に特に重要な影響を与えることを我々は発見した。材料の粒子サイズは小さいほうが有利である。少なくとも95数量%且つ少なくとも90容量%の粉末材料粒子が、50μm以下の粒子サイズを有することが好ましい。「粒子サイズ」の用語は、粒子の相当する粒子直径を言い、例えばレザー光回折を用い測定できる。
関連粒子が、粒子の集塊または凝集体を含む複合粒子の場合、粒子サイズは複合粒子のサイズであり集塊または凝集体中の個々の粒子のサイズではない。
このような粒子サイズは、医薬錠剤芯用の塗装材料としては驚異的に小さく、事実このような小粒子サイズは、その凝集性の為に材料の製造や取扱を難しくする欠点を有するものと認識されている。しかしながら、静電塗装方法による医薬錠剤芯の塗装では、小粒子サイズの採用に特別な利点があり、欠点を取消して更に利点があることを、我々は発見した。例えば、小粒子により提供される、表面対質量の高比率は、粒子上の静電気力を慣性力に比較して増大させる。
静電気力の増大は粒子上の力を増大させる利点をもち、これが粒子を移動させて錠剤芯に接触させ、一方慣性力の減少は粒子を加速するに必要な力を減少させ且つ芯で後方に跳ね返り錠剤芯に到達する粒子の可能性を減少させる。少なくとも90容量%の粉末材料の粒子が20μm以下の粒子サイズを有する場合に、特に有利であることを我々は発見した。好ましくは、少なくとも95数量%の粉末材料の粒子が30μm以下の粒子サイズを有する。
特に、選ばれた粉末材料に関し、粒子が錠剤芯の表面から跳ね返る傾向が認められた場合、錠剤芯の表面に前処理組成物を適用した後に、錠剤芯を粉末材料供給源に近接して保持させる。前処理組成物は、芯表面による粒子捕捉を改善でき、750μmもの大きさの大粒子を塗装材料として使用を可能にすることができた。前処理組成物に、液体が使用でき、粒子に作用する力を増し粒子を芯上に保持させる。前処理を採用する場合は、好適には少なくとも90数量%の粒子が、300μm以下のサイズであり、好適には少なくとも50数量%の粒子が、200μm以下のサイズである。
粒子サイズが極めて小さくなった場合、粉末の取扱に関する困難さは厳しくなる。従って、少なくとも50容量%、好適には少なくとも75容量%、最適には90容量%の粉末が、少なくとも5μmの粒子サイズを有することが、好都合である。
1つの好ましい粉末塗装材料において、平均粒子直径は約10μmであり、実質的に100μmより大なる直径を有する粒子を含んでいない。
好適には、少なくとも30容量%の粉末粒子が、5μm〜25μmの範囲の粒子サイズを有している。
粉末粒子が狭い範囲の粒子サイズをもつことが、また特に重要であることを我我は発見した。好適には少なくとも30重量%、より好適には少なくとも75重量%の粒子が、x〜2xの範囲、より好適にはx〜1.5xの範囲、最適にはx〜1.25xの範囲にある粒子サイズを有し、但しxは粉末の粒子サイズを表すものである。
例えば、比較的小サイズの粒子を有する粉末では、好適には少なくとも30重量%の粒子が、10μm〜20μmの範囲、より好適には10μm〜15μmの範囲、最適には10μm〜12.5μmの範囲にある粒子サイズを有する。
粒子が比較的大きい場合で、例えば前記のように前処理を行うならば、粒子サイズの好ましい相対的ばらつきは、相対的に小サイズの粒子に対するより通常小さくなる。
粉末の良好な均一塗布を、錠剤芯に、そして芯から芯へ実施するに関して、粒子サイズの範囲が大きい粉末は、粒子サイズの範囲が小さい粉末に比較して不利になることを、我々は見いだした。これは、或る粒子サイズを有する粒子が、より小さい又はより大きいサイズの粒子と比較したとき、錠剤芯上に優先的に塗装される故であると思考される。このことは、新規に仕立てたバッチの粉末材料で塗装した1つの塗装芯と、同一バッチで比較的あとで塗装した別の塗装芯で、芯の塗装の質の違い及び塗装の質の変化に繋がるものである。
粉末塗装材料が、粉末塗装材料の重量を基準にして10重量%より多くない、好適には5重量%以下、より好適には3重量%より多くない水分量(乾燥時の水分損失により測定)を有することが好都合である。
幾つかの異なる静電気効果があり、本発明の第1の観点に従って、粉末を用い医薬錠剤芯を塗装する静電塗装方法でも使用でき、そして異なる効果の利用に特に適合した幾つかの異なる粉末の電気的特性がある。3つの異なる効果と粉末の関連特性をここで説明し、各々が他から独立し又は他の1またはそれ以上と関連して使用できることが評価されるに違いない。
第1の可能性は、粉末の粒子中に一時的双極子を誘導することであり、その後に双極子と、粉末の供給源および錠剤芯間の領域の電場との相互作用により粒子が錠剤芯の方向に導かれる。好ましくは塗装材料は108〜1016Ωmの範囲の固有抵抗を持っている。
第2の可能性は、粉末の粒子に正味電荷を適用することである。この正味電荷は、摩擦帯電的にまたはコロナ帯電により導入される。それ故に、塗装材料はこのような正味電荷に対し好ましくは受容性であり、電荷を保持(材料を錠剤芯上に十分導く程度に長く)できる。
第3の可能性は、粉末の粒子に永久双極子、または半永久双極子を与える事である。このような「エレクトレット」は、粉末供給源と錠剤芯間の領域に働く電界との相互作用により錠剤芯の方向に導かれるであろう。このように、塗装材料はエレクトレットを含んでもよい。
第4の可能性は、鉄または他の磁性材料又は常磁性材料を用いた粉末材料中に磁気双極子を与えることである。
粉末材料に適用された全体的な正味電荷に依存することなく、および粉末材料中の永久的な植えつけ電荷に依存することなく、粉末材料が錠剤芯に向かうことができるのは好ましい。このように、粉末材料が静電気力の作用下で移動に敏感であることは好ましく、その感度は以下に明示する試験により測られる。
粉末材料が静電気力の作用下で移動に敏感であるか否かを測るには、以下の試験を行う。
0.5gの粉末材料の試料を採り、これを65%より大きくない相対湿度の環境中で接地電位に保ち水平に配置した導電性金属板上に置く。この粉末材料を単分子層に近い厚さに拡げる。粉末材料をその状態に30分間放置した後、導電性の直径5mmの丸い金属探針を粉末材料の中心の上方10mmに置き、高電圧を最初+10KV、次に−10KV(電流は約5μAに制限)で約10秒間探針に適用する。全体としての材料を代表する粉末材料の粒子が、どちらか一方の高電圧適用中に、上方に引き寄せられて探針に接触すれば、その試験結果は、粉末材料が静電気力の作用下で移動に敏感であることになる。粉末材料の粒子が、上方に引き寄せられず探針に接触しない場合、または或る種の粒子だけが引き寄せられ、その引き寄せられた粒子が全体として材料を代表していないならば、試験結果は、粉末材料が静電気力の作用下で移動に敏感でないことになる。
粉末材料の感度は、当然、粉末の電気的特性と他の物理的特性、例えば粉末の粒子サイズとの組み合わせに依存する。
塗装材料の粒子が帯電(例えば、摩擦帯電的に)して芯表面に付着するには、粒子が実質的に全て同一記号の電荷になることが、特に好都合である。一群の粒子がプラスとマイナスの電荷の混合物を含む場合、不満足な塗装が芯表面に生成することが判った。粉末を荷電する場合、全粉末が実質的に同一記号の電荷となるような組成物から粉末が構成されることが好ましい。さらに、粒子が同一記号の電荷でない場合、粉末材料が過剰噴霧され塗装工程の効率を低下させる。また、殆どの粒子が実質的に同じ大きさの電荷をもつことが好ましい。
材料は1成分以上から成る故、成分の相対的割合を調節することにより、粉末材料の特性を変更できる。一般に、粉末材料の特性に言及する場合、その特性は、全体としての材料で示される特性であり、材料の1つまたはそれ以上の成分が単独でその特性を示すことはないと言うことである。しかし、全体としての粉末塗装材料ではなく、粉末塗装材料の1つ又は数種の成分が、下記の特性を示す場合には、それは満足すべきものとなる:例えば、低温度で薄膜塗装を形成する材料の長所が、その特性を示す材料の2つ又はそれ以上の成分中の唯一の成分によって、達成される;他の成分が固体粒子のままであり、薄膜塗装に変換する粒子に比べより大なる重量割合を表す;このような場合、2つの成分の粒子サイズに実質的なバラツキがある;例えば、薄膜塗装に変換された粒子は、5〜20μmの範囲の粒子サイズを有し、一方固体粒子として残る粒子は実質的により大きくなる。
異質な成分の1つが、粉末材料に必要な静電的特性を与える働きをすることがある。例えば、1つの異質な成分が、摩擦帯電的に及び/又はコロナ帯電的に帯電され、及び/又はエレクトレットまたは磁石となり、及び/又は、ここに記載する試験で定めるように、静電気力の作用下で移動に敏感になることがある。
粉末材料の化学的特性は、塗装を形成する効率と外観に重要である。
材料の化学的特性を論じるとき、複数の成分から成る材料を処理することが好都合であり、以下の議論で明らかにされるように、同一化合物が1つ以上の成分として使用され、それ故に粉末材料が2つ以上の成分から成ることに関する以下の記述中の言及は、成分が異なっているものと特に見なす場合を除き、2つ以上の異質な成分が必然的に存在することを要求しているとは見なすべきではない。
粉末材料が、好ましくは250℃以下の温度で、より好ましくは200℃以下の温度で溶融して芯表面に連続薄膜を形成できる、第1成分を含むことが好ましい。上で議論したように、溶融は、上記温度範囲内で第1成分の融解、軟化または架橋の形態をとることができる。
第1成分が水性媒体に対し実質的に可溶性であることが好ましい。通常、第1成分は、中性の水性媒体に対して可溶性であり、選定されたPH範囲、例えばPH3〜PH6、またはPH8〜PH14にのみ溶解する。
好ましくは、第1成分は、ポリオキシエチレン、糖アルコール、と不飽和または飽和脂肪酸とエステルの1またはそれ以上から成る。第1成分は、250℃以下の温度で溶融するセルロース誘導体、例えばヒドロキシプロピルセルロースを含むことができる。全てのセルロース誘導体が第1成分として使用できるのではなく、例えばヒドロキシプロピルメチルセルロースは要求される溶融特性をもたず、且つ加熱により炭化する。
第1成分は、ポリエチレングリコールを含むことができ、該グリコールは良好な溶融特性をもち、且つ処理後、基材表面に良好な連続薄膜を形成できる。
好適な糖アルコールは、キシリトールであり、この材料は適切な電気的特性を有し、且つ適切な温度で融解して医薬錠剤芯の塗装における塗装材料として有用である。
その他の第1成分として使用可能な材料は、ワックスとオイル、ワックスまたはオイルのアルコール、ポロクサマー、アルキルナフタレン、例えばジエチルフタレート、クエン酸とエステルを含む。前記粉末の成分が液体の場合、成分を液体形態で単純に他の成分に添加でき、また、例えば粉末形態の担体材料と共に提供してもよい。
適切な溶融特性をもつ他の化合物が存在してもよく、上記は単に例示に過ぎない。
第1成分は、正に1つの化合物から成ることもあれば、2つまたはそれ以上の化合物を含んでもよい。
多くの場合、最も望ましい溶融特性を有する成分が、最適の電気的特性を備えていないし、及び/又は塗装の望ましい仕上がり、被覆または外観を提供しないものである。従って、上記の如く必要な電気的特性を有する第2成分を用いることが好ましい。
しかし、第1成分が、第2成分の所望する電気的特性を持ってもよく、また第2成分が、第1成分の所望する溶融特性を持ってもよいことは、理解すべきである。
第2成分は、アクリル酸、アクリル酸のポリマーとコポリマーおよびその誘導体、例えばポリメチルアクリレート、ポリアルケンとその誘導体、エステルを含み、アリールエステルとその誘導体、ポリビニルアルコールとエステル、セルロースとその誘導体、例えばセルロースエーテルとセルロースエステル(架橋型または非架橋型)、例えばエチルセルロース等の1つまたはそれ以上、1つまたはそれ以上の腸溶性ポリマー、例えばセルロースアセテートフタレートおよびヒドロキシプロピルメチルセルロースフタレートから成る。第2成分は、1つ又はそれ以上の生分解性ポリマー、例えばポリラクチド、ポリグリコリド、ポリヒドロキシブチレート、ポリヒドロキシバレレート、エチレンビニルアセテートコポリマー、とポリ酸無水物(ホモまたはヘテロポリマー)の1つ又はそれ以上を含んでもよい。第2成分は、ポリエチレンオキシドでもよい。
既に述べたように、第1成分と第2成分が同一化合物を含む可能性があるが、多くの場合は第1と第2成分は異質な化合物である。例えば、第1と第2成分が、それぞれキシリトールを含んでもよいが、しかしこの場合には、粘度調節剤と結晶化抑制剤を添加して第2成分に所望の溶融特性を与えるべきである。
2つまたはそれ以上の異質な成分を含む塗装材料は、異質な成分の分散を改善する分散剤成分を含むことが好ましい。分散剤成分は、好適にはアニオン性、カチオン性またはノニオン性の界面活性剤であり、しかし通常界面活性剤と呼ばれないが同様な効果を有する他の化合物でもよい。分散剤成分は、共溶剤であってもよい。
分散剤成分は、例えば、ラウリル硫酸ナトリウム、ドキュセイトソジウム、トゥイーン(ソルビタン脂肪酸エステル)、ポロクサマー、とセトステアリルアルコールの1つ又はそれ以上でもよい。第1及び/又は第2成分の化合物のように、分散剤成分は同一化合物を含んでもよい。上記の如く、第3と第1成分が共にポロクサマーを含んでもよい。材料が、材料の重量を基準にして、少なくとも1重量%、好適には2〜5重量%の分散剤成分を含むことが好ましい。
粉末塗装材料が減摩成分を含み、粉末塗装材料粒子間の摩擦力及び/又はその他の力を減少させ、粉末の流動性を改善することは、好都合である。減摩成分は、二酸化チタン、コロイダルシリカ、タルクまたは澱粉、またはそれらの混合物などがある。
塗装材料を「即時」放出型錠剤に用いるとき、粉末塗装材料が、塗装を破壊し得る崩壊剤を含むことが好都合である。錠剤芯上の塗装の場合、塗装中に崩壊剤の含有は、錠剤が摂取されたときに直ちに塗装の崩壊を促進する。
崩壊剤は、水分と接触したとき急速に且つ強力に膨潤するものであり、それにより塗装を破壊する。或る崩壊剤は、膨潤して数秒以内に元の容積の40倍になる。適切な崩壊剤の例は、澱粉グリコール酸ナトリウム塩(架橋型)とカルボキシメチルセルロースナトリウム塩(架橋型)がある。
替わりに、または加えて、崩壊剤はウイッキング型でもよく、この型は塗装を通して錠剤芯へと水分浸透させるが、錠剤芯から塗装を通して水分の逆行を防ぎ、それによって塗装を破壊させる。ウイッキング型の適切な崩壊剤の例は、天然の澱粉、架橋型ポリビニルピロリドン(クロスプロビドン)がある。
崩壊剤は、ガス発生型、例えば炭酸ナトリウム、炭酸水素ナトリウムとソジウムグリシネートでもよい。
好適には、粉末塗装材料は10容量%以下の崩壊剤を含有する。好ましくは、粉末は、5重量%以下、好適には2重量%以下、より好適には1重量%以下、最適には約0.5重量%の崩壊剤を含有する。
好ましくは、粉末塗装材料は、1またはそれ以上の不透明化剤、例えば二酸化チタンとタルクをさらに含有する。好ましくは、材料は、材料の重量を基準にして50重量%以下、好適には40重量%以下、より好適には30重量%以下、最適には約10重量%以下の不透明化剤を含む。
好ましくは、粉末塗装材料は、さらに1またはそれ以上の着色剤、例えば金属酸化物またはレーキ、例えばアルミニウムレーキ、酸化鉄、染料を含み、1またはそれ以上の味覚調節剤、例えばアスパルテーム、アセサルフェイムk、シクラミン酸塩、サッカリン、砂糖、及び糖アルコールまたは風味剤等を含むことができる。好ましくは、材料は、材料の重量を基準にして、10重量%以下、好適には1〜5重量%の着色剤を含み、そして材料の重量を基準にして、好適には5重量%以下、より好適には1重量%以下の風味剤を含む。風味剤が甘味料の場合には、好ましくは、材料は0.5重量%以下の甘味料を含む。好ましくは、材料は、材料の重量を基準にして、5重量%以下の着色剤と風味剤を含む。減摩成分、不透明化剤、着色剤および味覚調節剤は、粉末塗装材料の他成分化合物と同一の化合物であってもよいと認められる。
粉末塗装材料は生物活性材料を含有することができ、これは生物学的環境で工程速度を増減する材料である。生物活性材料は、生理学的に活性な材料であればよい。活性材料を含有する塗装材料は、例えば同一または異質の活性材料を含む錠剤芯に適用でき、または非活性材料含有錠剤芯に適用できる。活性材料は、1またはそれ以上の化合物を含有するできる。活性材料は、酸消化・運動誘導剤、緩下剤、制痢剤、結腸・直腸薬、膵臓酵素と胆汁酸、抗不整脈薬、抗狭心症薬、利尿剤、抗高血圧薬、抗凝固薬、抗血栓薬、フィブリン溶解薬、止血薬、脂肪欠乏症薬、抗貧血・好中球減少病薬、催眠薬、抗不安薬、抗精神病薬、抗うつ薬、制吐薬、鎮痙薬、CNS刺激薬、鎮痛薬、解熱薬、抗片頭痛薬、非ステロイド性抗炎症薬、抗通風薬、筋弛緩薬、神経筋薬、ステロイド、低血糖症薬、高血糖症薬、診断薬、抗生物質、抗真菌性薬、抗マラリヤ薬、抗ウイルス薬、免疫抑制薬、栄養薬、ビタミン、電解質、食欲抑制剤、欲求抑制剤、気管支拡張薬、去痰薬、鎮咳薬、粘液溶解薬、うつ血除去薬、抗緑内障薬、経口避妊薬、及び/又は抗腫瘍性薬を含む。
粉末塗装材料を適用する錠剤芯は、通常1またはそれ以上の不活性薬品を含んでいる。不活性薬品は、希釈剤、例えば乳糖、蔗糖、ブドウ糖、澱粉、セルロース、微晶質セルロース;結合剤、例えばポリビニルピロリドン、澱粉粘液、ゼラチン、アラビアゴム;崩壊剤、例えば架橋型カルボキシメチルセルロースナトリウム塩、澱粉グリコール酸ナトリウム塩、架橋型ポリビニルピロリドン;潤滑剤、例えばステアリン酸マグネシウム、フマル酸ナトリウムステアリル;グライダント、例えばコロイダルシリカ、タルク;界面活性剤、例えば湿潤剤で、ラウリル硫酸ナトリウム、ドキュセートナトリウム;着色剤;風味剤及び/又はガス発生剤、例えば重炭酸ナトリウムとクエン酸を含むことができる。
錠剤芯は、また上に掲載した1またはそれ以上の活性材料を含むことができる。好ましくは、粉末塗装材料は、粉末塗装材料の重量を基準にして、少なくとも0.5重量%、より好適には1重量%の活性材料を含む。例えば、錠剤上の10mgの塗装は、概略少なくとも0.05mgの活性材料を含有できる。
粉末塗装材料の成分を混合する割合は、粉末塗装材料を構成する材料と塗装する基材の性質に大きく依存する。所望の電気的および溶融特性が得られるように割合を調整する。通常、粉末塗装材料は、少なくとも10重量%、好適には少なくとも15重量%、最適には約20重量%の第1成分を含有する。通常、粉末塗装材料は、少なくとも10重量%、好適には少なくとも20重量%、そしてより好適には少なくとも40重量%の第2成分を含有し、それぞれ場合、粉末塗装材料の重量を基準にした。好ましくは、第2成分と第1成分の重量比率は、約3:1である。成分比率は、第1と第2成分を構成する材料に依存する。その比率は2:1または1:1である。
本発明は、さらに医薬基材の静電塗装用塗装材料を提供するもので、該塗装材料は活性材料を含有する。上に示した如く、活性材料を含む塗装材料は、例えば同一または異質の活性材料を含む錠剤芯に適用され、または非活性材料を含む芯に適用される。
活性材料の極少量摂取を錠剤形態で管理しようと試みる場合、活性材料を大量の非活性「充填」材料と混合して、管理可能サイズの錠剤を作成する。従来、活性材料と充填材料を単純に一緒に混合し、得られた混合物の摂取量を錠剤化していた。各錠剤中に含有される活性材料量の正確な管理が難しく、摂取量の均一性が不十分であることが判っていた。これは、特に、各錠剤が要求する活性材料量が少量の場合に認められた。
錠剤表面に活性材料を適用することにより、極少量の活性材料を正確に錠剤に適用でき、摂取量の再現性を改善できることが判明した。
塗装材料に含有される活性材料の量は、勿論、基材に適用される活性材料の摂取量の大小および形成される塗装の厚みに依存する。通常、材料は、塗装の重量を基準にして、少なくとも0.5重量%の活性材料を含有する。
塗装材料が、粉末塗装材料であることが好都合である。それ故、上に述べた方法と同様な方法を用いて塗装材料を適用することが便利であり、塗装材料は基材に対し正確に且つ過剰噴霧もなく適用される。
好ましくは、活性材料を含有する塗装材料は、50μmより大きくない粒子サイズを有する少なくとも90数量%の粒子を含有する。好ましくは、少なくとも90数量%の粉末粒子が、30μm以下、より好ましくは20μm以下の粒子サイズを有する。
また、本発明は、基材の静電塗装、特に医薬錠剤芯の静電塗装において、活性材料を含む塗装材料の使用を提供する。
また、本発明の第1の観点は、粉末材料で医薬錠剤芯を静電塗装する方法、と上に定義した粉末材料を提供する。
さらに、本発明の第1の観点は、基材の静電塗装用粉末塗装材料を提供し、粉末は上記の如き方法で得られる。
なお、さらに、本発明の第1の観点は、錠剤芯および上に定義したような粉末塗装材料を含む医薬錠剤を提供する。
さらに、本発明の第1の観点は、医薬錠剤芯を粉末で塗装する方法を提供し、該方法は、電界中で粉末塗装材料の供給源に近接して錠剤芯を保持し、且つ少なくとも芯の部分を塗装材料の電位と異なる電位に保持して、電位差を適用して粉末を粉末供給源から錠剤芯および芯表面の方向に導き、粉末塗装材料で塗装することを特徴としている。
錠剤芯の塗装は、電界の適用及び少なくとも錠剤芯の部分と粉末材料間の電位差の結果として、粉末材料を錠剤芯に向けて誘導する故、粉末材料の到達地点は、少なくとも最初のうちは錠剤芯の表面に制限される。若し、それが露出表面にだけ配列されるなら、それは粉末材料の近傍であり粉末材料に対し適切な電位差がある場所である。
本方法の特別な進歩は、連続工程で実施できることである。
錠剤芯を、粉末塗装材料の供給源に近接する領域を通る移送手段により移送することが、好都合である。錠剤芯を移送することにより、塗装工程の全般を通して錠剤芯を穏やかに取扱い、壊れやすい錠剤芯でさえも損傷しないことを保証できる。
本方法は、壊れやすく従来の錠剤塗装方法に耐えられない錠剤芯の塗装に使用できる。このように、本発明は、従来の形状をもち且つ広範囲の組成をもつ錠剤の製造を可能にした。また、従来にない形状の錠剤、例えば従来の円形面ではない、むしろ反対の平面をもつ錠剤も本発明の方法で製造できる。このような平面の錠剤は通常非常に壊れやすくて従来法では塗装できなかった。さらに、平面の錠剤はしばしば一緒に繋がり双子の錠剤や錠剤群を形成し、従来の塗装方法では適正に塗装できなかった。
錠剤芯が、粉末塗装材料供給源に近接する上手から保持され、そして粉末が、供給源上方から基材下部表面に移動する。
上に明示した塗装方法で作成した錠剤芯は単に一部分を塗装したものであり、本塗装方法は更なる次の工程を含み、該工程は、電界中で粉末塗装材料供給源に近接して塗装錠剤芯を保持し、錠剤芯の少なくとも一部分を塗装材料の電位と異なる電位に維持し、電位差の適用により粉末を、粉末供給源から錠剤芯に向けて誘導し、そして錠剤芯の非塗装面を粉末塗装材料で塗装するものである。このよにして、錠剤芯の全表面に容易に塗装を施すことが可能であり、また錠剤芯の異なる部分を異質の塗装材料で塗装することも可能である。例えば、錠剤の各反対面に色の異なる塗装を行うことができる。
さらに、本発明の第1の観点は、上に明示した方法によって静電塗装を施した医薬錠剤を提供するものである。
本発明の第1の観点に従い、特に医薬錠剤芯塗装のために、および塗装の適用から材料に課せられえる過酷な条件に対処するために、粉末塗装材料および塗装方法を開発した。医薬錠剤芯塗装に適した材料と方法を開発したが、我々は、さらに本材料および方法が有効に使用できる他の用途に思考を拡げた。例えば、医薬産業界で、本材料および方法は、経口摂取されないその他医薬製品の塗装に使用可能であり、例えば、ペッサリー、ブージーまたは座薬、または他の医薬基材に使用可能である。
本発明の第2の観点によれば、医薬基材の静電粉末塗装用粉末塗装材料が提供され、該材料は1またはそれ以上の下記の特性を有している。
a)人間及び/又は動物の食用に適する、
b)少なくとも2つの異質な成分から成り、好ましくは粒子は複合粒子から成る、
c)大気圧で250℃以下の温度で溶融して薄膜塗装を形成する、
d)少なくとも30重量%の粒子が5μm〜20μmの範囲の粒子サイズを有する、
e)静電気力の作用の下で移動に敏感であり、ここに明示する試験法によりその感度を測定する。
粉末塗装材料が生理学的に許容できる材料であり且つ好適には医薬的に容認できる材料であることが、特に好ましい。本材料は、医薬錠剤芯塗装用材料に関する説明において前記したその他の特性を有することができる。
また、本発明は、基材の静電塗装用の少なくとも2つの異質な成分を含む粉末塗装材料を製造する方法を提供し、本方法は該少なくとも2つの異質な成分を同時処理する工程を含むものである。
さらに、本発明の第2の観点は、上に明示した粉末塗装材料により医薬基材を静電塗装する方法を提供する。
ここで、特定サイズを有する某数量%の粒子と言うような、数量%の粒子に関する記載がある場合、該粒子は同一容量%の該サイズの粒子を有することが好ましい。さらに、容量%の粒子に関する記載がある場合、該粒子は同一重量%の粒子を有することが好ましい。
実施例により、医薬錠剤芯の塗装方法および医薬錠剤芯の塗装用に適する数種の粉末塗装材料について、添付図面を参照しながら説明する。
図面において、図1は、錠剤芯塗装用装置の側面図を概略示し、図2は、図1の装置のドラムの断面を概略示す。
図1に概略図示した装置は、医薬錠剤芯の両面を塗装する装置である。本装置は、第1回転ドラム12につながる、錠剤芯供給用傾斜シュートを含んでいる。ドラム12は、スチール製であり且つその外表面に円形の窪み14(図2)を有する。後で説明するように、吸引により各窪み内に錠剤芯が保持される。
ドラム12は、矢印の方向に回転できる。ドラム12の円周に近接し、錠剤供給シュート10の下流に、静電噴霧ガン16を含む準備位置Aがあり、この位置は、錠剤芯の露出面をガン16から発せられる荷電液滴で被覆する。準備位置の下流は、振動粉末皿18を含む塗装位置Bであり、芯塗装用粉末を保持、流動化し且つ塗装領域D内での再循環を行う。塗装位置の下流はヒーター20を含む溶融位置Cである。溶融位置Cを通過後、塗装芯は冷却位置(図示しない)を通過し、ここで冷却空気が錠剤上または周囲に誘導されて溶融した塗装を冷却する。
第2ドラム12’は、第1ドラム12に近接しており、ドラムの締付け部は溶融位置Cの下流になる。第2ドラム12’は、矢印の如く第1ドラム12に対向して回転する。第2ドラム12’は、ガン16’を含む準備位置A’、粉末皿18’を含む塗装位置B’、ヒーター20’を含む溶融位置C’と冷却位置(図示しない)を装備している。
錠剤芯収集シュート22は、溶融位置C’の下流で、第2ドラム12’から離すように下方に傾斜していて、塗装済の錠剤芯を取り出し次の処理および包装工程につなげる。
第1ドラム12について、図2を参照して詳細に説明する。このドラムは、回転可能な外板24を含み、該外板の外側表面に窪み14がある。図2には、代表的な5個の窪みだけを示してある。実際には、外板24の周囲の円周列に非常に多くの窪みが均等に位置しており、またドラムの幅を横切る何本もの円周列があり、そこには1枚の連続外板または並んで固定された数枚の外板が形成されていることが判る。ドラム上の窪み14の形状と寸法は、錠剤芯がドラム上にあるときに、芯の全片面と側壁の深さの1/2が露出するように保証されている。円形錠剤芯の場合、錠剤芯直径に近い窪み直径が好適である。或る適用例では、窪みの深さを、芯の厚みの少なくとも50%になるように、塗装材料粒子に対し露出して、芯の最初の1面の露出、およびその後に他の面の露出を実施して芯を完全に被覆する。
ドラム上の各窪み14は、その他の窪みと電気的に絶縁されており、且つ内方向に放射状に延び、しかしドラムの中心の手前で終わる摘出アーム26をそれぞれ備えている。摘出アーム26は、外板24の内表面に取り付けられ、外板24と共に回転する。各々関連する摘出アーム26と窪み14は、共に移動電極を形成し、窪み中の芯を帯電させる。それぞれの窪み14は、重力のような外力に対抗する芯保持手段、例えば、吸引連結管30に繋がっている壁を通る通路28を有し、前記吸引連結管30は外板と共に回転せず、ドラム周辺の一部の周囲に、第1ドラム12と第2ドラム12’間の締付け部に近接する芯供給シュートの直ぐ上流から内部に伸びている。
接地された固定のアーチ型第1電極32は、準備位置Aに相当する角度位置でドラム内側に置かれる。アースに対して電位差をもつ固定アーチ型第2電極34は、塗装位置Bに相当する角度位置でドラム内側に置かれている。固定電局のアーチ外表面は、ドラムの中心から同一半径距離にあり、移動電極の摘出アーム26の自由端になる。外板24の回転に伴い、移動電極は第1、第2固定電極に順次接触する。ドラム12は、塗装粉末のようにアースに対し同一電位差、好ましくは接地電位、好ましくは粉末皿18に接続して保持される。
第2ドラム12’は、第1ドラムと同様に構成され、窪みを備えた回転する外板、摘出アーム、と第1、第2固定電極、と吸引連結管から構成される。第1と第2固定電極の角度位置選定は、第2準備位置A’と第2塗装位置B’に相当し、そして吸引連結管は、芯収集シュート22に近接する2個のドラム間の締付け部の直ぐ上流から伸びている。
使用時、芯は連続的に芯供給シュート10に供給される。芯は、芯供給シュート10を下り、第1ドラム12の回転外板24中の窪み14に入る。この角度位置で、窪みは吸引連結管30上に位置し、それ故、前記芯は、外板中の通路28による吸引で窪み中に保持される。外板24は回転し続けて前記芯を準備位置Aに運び、その地点で、窪み14に取り付けた摘出アーム26は、第1固定電極32に接触して移動電極を接地し、このようにして芯が窪みに保持される。接地された錠剤芯が静電噴霧ガン16を通過するときに、その露出表面に捕捉力向上液体、例えば、ポリエチレングリコールの帯電液滴が噴霧される。
外板24は回転し続けて、錠剤が塗装位置Bに接近したとき、移動電極26を第1固定電極32との接触から外して第2固定電極34と接触させる。ポリエチレングリコール処理した露出した芯表面は、アースに対して電位差を有し、塗装粉末材料は、静電気力により粉末皿18から芯表面に誘導される。ドラム表面と粉末を互いにアースに対して同一電位差に且つ芯をアースに対して異なる電位差に保持することにより発生する電位は、粉末が芯に引きつけられるがドラム表面には実質的に粉末が付かない状態を保証している。
外板24は回転し続けて、移動電極26を第2固定電極34との接触から外して、芯を溶融位置Cに運び、その位置でヒーター20が芯の塗装表面の粉末を溶融して薄膜を形成させる。
外板24が回転を続けるに伴い、芯は溶融位置Cを離れ、冷却位置(図示しない)を通過すれば、芯を運ぶ窪みは最早や吸引連結管30上に位置しなくなる。芯は第1ドラム12から第2ドラム12’上の外表面にある窪み中に落下し、ドラム12’上ではその非塗装表面を外向きにする。窪みは第2ドラムの吸引連結管30に接続する。芯が第2準備位置A’、塗装位置B’、溶融位置C’と冷却位置を移動するに従い、芯の塗装が完了する。第2塗装位置にある塗装粉末材料は第1塗装位置の塗装粉末材料と同一でもよく、また異なることもある。このようにすれば、異なって塗装された表面をもつ錠剤が製造できる。塗装した錠剤が収集シュートに近づくとき、芯を運ぶ窪みは吸引連結管から外れ、塗装錠剤はシュート中に落下し、そして更に処理、包装が行われる。
ドラム自体は、好適には、直径で少なくとも60mmであり、幅で最小錠剤直径より小でなく、少なくとも1/2rpmで回転する。吸引連結管の吸引圧力は、重力に対し錠剤を保持するに有効な大きさであり、好適には大気圧下で0.2〜0.6バールである。
準備位置A、A’における静電噴霧ガン16と16’で、半導電性の非蒸発性流体、例えばポリエチレングリコールまたはその水溶液が、0.1〜1ml/分の速度で内径0.05〜2mmのスチール製毛細管に供給される。ドラム上の各芯がガンを通過するとき、前記毛細管がアースに対し電位差をもつ電流制限した高電圧(30〜100μAで最高50kVまで)に接続され、そして毛細管からドラム上の芯に向けて、帯電液滴の噴霧体が放射される。ドラム上の芯が準備位置で接地される故、帯電液滴が毛細管と芯間の電界により誘導され、芯の露出表面に達し、其処で捕捉される。芯は、準備位置において、対アース電位差で保持されるが、ただし芯が毛細管に対しても電位差を有する場合に限る。この場合、固定のアーチ型電極32は、アースに対し電位差がある。各芯が準備位置を離れるとき、電圧を切ること及び抵抗(1〜10MΩ)を介し毛細管を接地することにより、各毛細管からの液滴の供給が管理される。この方法は錠剤芯間の液滴の遮断をシャープにする。
塗装位置BとB’で、振動供給器により、粉末塗装材料が振動皿18と18’に供給される。各皿上で、ならし板を用いて皿中の粉末の高さを一定にする。粉末は振動流動化され、連続的に再循環される。前記の皿は、各ドラム上の錠剤芯により掃引されるアーク下で、アースされた金属小片を有するプラスティック材料製でもよく、または金属製でもよい。粒子帯電の新しい方法は、摩擦帯電的な帯電である。前記の皿は、好ましくは50〜150mmの長さと3〜40mmの幅である。2色または多色の面または1以上のポリマー組成物を有する面を提供するために、1以上の皿を使用するなら、皿の寸法はそれに相応しく変更できる。錠剤芯は、5μAまでの制限電流で3〜15kVの電圧で帯電される。
溶融または乾燥位置CとC’で、芯表面にエネルギーを付与して粉末を溶融し、芯の露出表面に均一塗装を提供する。好ましくは、エネルギーの提供は赤外線領域の集束照射でなされる。エネルギーの性能要件は塗装材料で略決まる。溶融または乾燥後に、送風機を用いた冷却工程で、塗装は固定される。
本発明による好適な塗装装置は、毎時300,000錠剤芯まで塗装可能である。
図1と2を参照して上に記載した錠剤芯の塗装方法で、使用に適する粉末塗装材料の実施例を以下に説明する。
実施例1
乾燥粉末塗装材料を以下の方法で調整した。
(a)以下の化合物(重量%)を含有する試料を、高剪断ミキサーを用い前もって混合した。
55.5% ユードライトRS(商標)(アンモニオ−メタクリレートコポリマー微粉体)
18.5% ポリエチレングリコール(高分子量:約20000)
15.0% 二酸化チタン
5.0% アルミニウムレーキ
5.0% ラウリル硫酸ナトリウム
0.5% エクスプロタブ(商標)(澱粉グリコール酸ナトリウム塩)
0.5% アエロジル200(商標)(コロイド性二酸化珪素)
混合前、前記試料の各成分の粒子サイズは下記の通りであった。
二酸化チタン 50容量%が5μm以下
アルミニウムレーキ 50容量%が1μm以下
ラウリル硫酸ナトリウム 50容量%が100μm以下
ユードライト 50容量%が40μm以下
ポリエチレングリコール 50容量%が60〜70μm
(b)前記の事前の混合物を下記の方法で湿式造粒した。上の(a)で得た混合物に水を徐々に添加し、高剪断ミキサー中で数分間混合して、粒状の混合物を得た。添加水の重量は、事前の混合物重量の約10〜15%であった。
(c)上の(b)工程で得た粒状の混合物を、流動床乾燥機中で約45℃の温度で約20〜30分間乾燥して、3重量%以下の水分含有量(乾燥損失として測定)を有する材料を得た。
(d)工程(c)で得た小粒を衝撃粉砕した後、流動エネルギー粉砕機を用いて微粉砕して粉末を得た。該粉末は、50容量%の粒子が20μm以下のサイズで、殆ど100容量%が60μm以下のサイズであった。粒子サイズ分布のピークは約10μmのところに見られた。
粉末は、先に明示した静電気力の作用下で移動に敏感であった。
(e)前記粉末で、前に記載した方法と装置を用いて、錠剤芯を塗装した。捕捉力向上液体による前処理は実施しなかった。赤外線源を用い錠剤芯上の塗装粉末を約130℃の温度に約5秒間加熱して、錠剤芯表面の粉末塗装を溶融させた。得られた塗装は、良好な不透明性を有し、滑らかで、光沢があり、そして明るい着色をしていた。塗装の厚みは100μm以下であった。
上記工程(d)で作成した粉末粒子の粒子サイズ分布を測定した。
100% 57.25μm以下
70.29% 22.04μm以下
5.58% 1.52 μm以下
粒子の約50%は、15.05μm〜32.29μmサイズであった。
粒子の約35%は、18.21μm〜32.29μmサイズであった。
平均粒子サイズは、19.17μm(1つの方式で計算した)であった。
実施例2
以下の化合物(重量%)を含有する試料を用い、
59.6% ユードライトRS(アンモニオ−メタクリレートコポリマー)
19.9% クルーセル(商標)(ヒドロキシプロピルセルソース)
15.0% 二酸化チタン
5.0% アルミニウムレーキ
0.5% クロスカルメロースナトリウム(架橋カルボキシメチルセルロースナトリウム)
実施例1の工程(a)から(d)に記載の方法で、粉末塗装材料を作成した。実施例1の工程(e)に記載したように、粉末材料を錠剤芯表面に塗装し、溶融させた。得られた塗装は、滑らかで、高光沢があり、強い色と良好な不透明性を有していた。この塗装は、従来の薄膜−塗装錠剤芯に期待する光沢に比べ、より高光沢であると判定した。
実施例3
以下の化合物(重量%)を含有する試料を用い、
39.75% ユードライトRS(アンモニオメタクリレートコポリマー)
39.75% クルーセル(ヒドロキシプロピルセルソース)
15.0% 二酸化チタン
5.0% アルミニウムレーキ
0.5% アエロジル200(コロイド性二酸化珪素)
実施例1の工程(a)から(d)に記載の方法で、粉末塗装材料を作成した。実施例1の工程(e)に記載したように、粉末材料を錠剤芯表面に塗装し、溶融させた。得られた塗装は、滑らかで、光沢があり、強い色と良好な不透明性を有していた。
実施例4
以下の化合物(重量%)を含有する試料を用い、
60.0% ユードライトRS(アンモニオメタクリレートコポリマー)
20.0% グリセロールモノステアレート
15.0% 二酸化チタン
5.0% アルミニウムレーキ
実施例1の工程(a)から(d)に記載の方法で、粉末塗装材料を作成した。実施例1の工程(e)に記載したように、粉末材料を錠剤芯表面に塗装し、溶融させた。得られた塗装は、滑らかで、無光沢であり、強い色と良好な不透明性を有していた。
実施例5
以下の化合物(重量%)を含有する試料を用い、
60.0% ユードライトRS(アンモニオメタクリレートコポリマー)
20.0% キシリトール
15.0% 二酸化チタン
5.0% アルミニウムレーキ
実施例1の工程(a)から(d)に記載の方法で、粉末塗装材料を作成した。実施例1の工程(e)に記載したように、粉末材料を錠剤芯表面に塗装し、溶融させた。得られた塗装は、半光沢で、強い色と良好な不透明性を有していた。
実施例6
以下の化合物(重量%)を含有する試料を用い、
46.5% ユードライトRS(アンモニオメタクリレートコポリマー)
28.0% クルーセル(ヒドロキシプロピルセルソース)
15.0% 二酸化チタン
5.0% アルミニウムレーキ
5.0% ポリエチレングリコール6000
0.5% アエロジル200(コロイド性二酸化珪素)
実施例1の工程(a)から(d)に記載の方法で、粉末塗装材料を作成した。実施例1の工程(e)に記載したように、粉末材料を錠剤芯表面に塗装し、溶融させた。得られた塗装は、滑らかで、強い色と良好な不透明性を有していた。
実施例7
以下の化合物(重量%)を含有する試料を、
56.25% ポリエチレングリコール
20.0% 二酸化チタン
18.75% ユードライトRS(アンモニオメタクリレートコポリマー)
5.0% アルミニウムレーキ
高剪断ミキサーを用いて調合した。調合前の状態では、ポリエチレングリコールとユードライトは、少なくとも50容量%の100〜200μmのサイズを有する粒子であって同様な粒子サイズであり、少なくとも50容量%の二酸化チタンとアルミニウムレーキは、1μm以下のサイズを有していた。
(b)乾燥した調合混合物を粉砕して、少なくとも50容量%の粒子が100〜200μmのサイズを有する300μm以下の粒子サイズの粉末材料を得た。
(c)ポリエチレングリコールの前処理噴霧を含む、上記の方法と装置を用いて、前記材料を錠剤芯に塗装した。赤外線源を用い錠剤芯上の塗装粉末を約130℃の温度に約5秒間加熱して、錠剤芯表面の粉末塗装を溶融させた。得られた塗装は、滑らかで、高光沢であり、強い色と良好な不透明性を有していた。この塗装は、従来の薄膜−塗装錠剤芯に期待する光沢に比べ、より高光沢であると判定した。
実施例8
以下の化合物(重量%)を含有する試料を、
56.25% ポリエチレングリコール
20.0% 二酸化チタン
18.75% ユードライトRS(アンモニオメタクリレートコポリマー)
5.0% アルミニウムレーキ
高剪断ミキサーを用いて乾燥調合し、調合混合物を実施例7の工程(b)の記載のように粉砕した。なお、上記成分は、調合前には、実施例7に記載の粒子サイズと同様の粒子サイズを有していた(ポリエチレングリコールはユードライトと同様の粒子サイズ)。得られた材料を、実施例7の工程(c)に記載したように、錠剤芯に塗装した。得られた塗装は、滑らかで、高光沢であり、強い色と良好な不透明性を有していた。この塗装は、従来の薄膜−塗装錠剤芯に期待する光沢に比べ、より高光沢であると判定した。
上記実施例では、全成分は粒子状の固体材料の形状であるが、粉末塗装材料は液体形状の成分を含有してもよい。The present invention relates to electrostatic coating of a pharmaceutical substrate with a powder coating material and powder coating material for coating a pharmaceutical substrate. In particular, the present invention relates to, but is not limited to, electrostatic coating of pharmaceutical tablet cores with powder coating materials and powder coating materials for pharmaceutical tablet core coatings. Reference is made to pharmaceutical tablets throughout the specification, and in particular, the present invention is often viewed as an application relating to conventional shaped pharmaceutical tablets, but this term refers to other products taken orally such as pellets, capsules and globules. Should be interpreted in a broad sense that also includes
Electrostatic coating of conductive substrates such as metal objects is well known. For example, in some paint spraying methods, the paint is charged and sprayed onto a metal object that is grounded. This method has been successful in forming a uniform coating film on a substrate.
Electrostatic coating of non-conductive substrates, especially pharmaceutical tablet cores, is quite difficult. For years, proposals have been made on electrostatic coating of tablets. For example, UK 1075404 proposes a device for tablet coating, in which fine particles of the coating solution are sprayed onto the tablets using a sprayer in a high potential field. As an example, the coating is dried using an infrared heater. However, this proposal has never been practiced on a substantially industrial scale, and the coating of pharmaceutical tablet cores is usually carried out batchwise by applying a liquid paint in a rotating drum. This liquid coating material may be supplied in powder form in some cases, but even if so, the coating material is used after being dissolved or dispersed in the liquid. Therefore, the coating material is not applied to the tablet core in powder form.
Application of liquid coating to pharmaceutical tablet cores is often easier than powder coating. It is difficult to fix the powder to the tablet, and in order to fix the coating to the core, it is necessary to convert the powder into a thin film without damaging the tablet core, which usually contains organic materials. Furthermore, uniform coating is required, and it is difficult to obtain a uniform powder coating on the tablet core.
If liquid paint is used, the paint must be dried. Theoretically, drying can be carried out at room temperature in some environments, however, tablet heating is important in the industry in terms of the speed at which the process is carried out, and the solvent used for liquid coating is evaporated. This is expensive because of the large amount of energy required. Another disadvantage of liquid coating is that useful liquids, preferably materials that do not dissolve or disperse properly in water, cannot be used for the coating material.
WO92 / 14451 relates to electrostatic powder coating of pharmaceutical tablets. The pharmaceutical tablet core is transported on a grounded conveyor belt, and electrostatically charged powder is sprayed toward the core to adhere to the core surface. Explains and illustrates how to form a powder coating. Thereafter, the powder coating is melted to give a molten film coating fixed to the core.
The disadvantage of such a method is that most of the powder sprayed towards the core is not charged and does not deposit on the core. This leads to waste of spray droplets and powder material, and makes it difficult to achieve uniform coating.
In a first aspect, the present invention attempts to provide a powder coating material suitable for electrostatic powder coating of pharmaceutical tablet cores, and provides a method for electrostatic coating of pharmaceutical tablet cores by using special powder coating materials. Attempts to facilitate electrostatic coating.
The first aspect of the present invention is to provide a powder coating material for use in electrostatic powder coating of tablet cores, particularly for coating methods defined below, and having special properties that give suitability for use in this method. It is. Preferably, the special properties of the powder coating material are defined below, and since the advantages afforded by these properties are influenced by the coating method employed, this method is also defined.
According to a first aspect of the present invention, the present invention provides a powder coating material suitable for electrostatic powder coating of a pharmaceutical tablet core, the material being pharmaceutically acceptable, capable of thin film coating processing, and Comprising composite particles, said composite particles being composed of two or more components having different physical and / or chemical properties.
It is important that the powder coating material is a pharmaceutically acceptable material. This in itself imposes severe constraints on powder coating materials, at least most of the powder coating materials commercially available for electrostatic powder coating processing are physiologically unacceptable and pharmaceutical tablets Commercially available materials for the core coating material are generally not suitable for electrostatic powder coating because of other inappropriate material properties.
The powder coating material of the present invention includes at least two different components, each having different physical and / or chemical properties. The use of a material composed of one or more components compared to the use of a one-component material makes it much easier to provide a powder material having the desired properties described above and elsewhere in the specification. For powder materials containing two or more extraneous components, we have found that improved coating is achieved when the powder contains several component composite particles.
If the coating method used is, for example, as described in the examples below, one or more coating material particles will be present if one or more of the components does not have the electrical properties required for coating on the core. It is particularly important to contain these components. If the particles are not composite particles, these particles consisting of components that do not have the required electrical properties may simply stay in the powder source and not be coated on the tablet core.
As used herein, the term “composite particle” refers to a particle formed from two or more different components. The composite particles are not homogeneous, and the composite particles have two or more regions each composed of fine particles of different components. The composite particles may be in the form of individual separate composite particles or may be agglomerates or aggregates of individual particles of different components, where the agglomerates or aggregates exhibit the behavior of separate composite particles. .
Advantageously, at least 50% by weight of the powder particles are composite particles. Ideally, virtually all particles need only be composite particles, which is not possible, especially when the particle size of the composite particles is small. If the powder includes two or more components having different physical and / or chemical properties, the composite particles advantageously also include other components. Ideally, virtually all composite particles are composed of individually separated particles that contain each of the heterogeneous components. However, in practice, satisfactory coating is obtained when the individual component particles form composite particles as aggregates or agglomerates.
Preferably two or more components are processed simultaneously. This simultaneous treatment consists of granulation, spray coagulation, spray drying or simultaneous grinding. If this co-treatment results in a relatively large size, for example granules, it is advantageous in some cases to carry out a subsequent grinding step to reduce the particle size. You may implement a miniaturization process newly.
As is well known, mixing of powder components usually results in a uniform mixture of components. However, in special cases, composite particles can be obtained by a mixing method by carefully selecting the mixing conditions, such as the initial particle size of the components and the mixing means.
According to the first aspect of the present invention, the powder coating material is a material that can be coated on the surface of the tablet core and then processed to form a thin film coating fixed to the core. Thus, the coating method of the present invention includes a step of forming a thin film coating fixed on the tablet core surface by processing the powder after coating the tablet core surface with powder. The thin-film coating is advantageously continuous, in which case the coating is not divided into separate parts, but there are small gaps that are not visible to the naked eye, for example, between the coating particles fixed together during the processing process. Existing. Thus, the paint is sintered. For some applications, it is preferred that no gaps exist in the thin film coating and / or that it be substantially homogeneous.
The powder material initially deposited on the tablet core is often easily removed by simply weakly adhering to the substrate surface. Because the mechanical strength of the tablet core itself is often small, the treatment to form a thin film coating is particularly advantageous when coating a pharmaceutical tablet core, and a thin film coating is used to provide strength, and the coated tablet To withstand the next process such as packaging and unpacking. Thin film coating can give the tablet core special strength, but is often very weak when separated from the core surface. The tensile strength of thin film coating as a free thin film is, for example, 8MNm-2Or less, and TiO in the coating material2It was found that the tensile strength decreased with increasing amount of.
When the tensile strength of the free thin film is small, it is particularly important that the thin film has a cohesive coating on the core surface with excellent adhesion to the tablet core.
When the powder material is converted into a liquid phase in the thin film coating forming step, the viscosity of the powder material in the liquid phase is preferably 500 Pascals or less, more preferably 75 Pascals or less.
It is an advantage that the powder coating material can be processed at a temperature of 250 ° C. or less, more preferably 200 ° C. or less, for forming a thin film coating. Conveniently, the powder coating material can be melted at a temperature below 250 ° C., more preferably below 200 ° C. under atmospheric pressure. It is important to process the powder without damaging the tablet core to form a coating around the tablet core, and this is due to the fact that many tablet cores containing organic materials are heat sensitive, so It imposes demands on it. The powder coating material preferably has a melting point in the range of 50C to 180C, more preferably in the range of 60C to 100C. For materials exhibiting a glass transition, the powder coating material preferably has a softening point in the range of 30 ° C to 180 ° C.
The above requirements place additional constraints on powder coating materials. Many materials do not melt and are carbonized by heat. Other materials that are meltable, however, need to be exposed to a heat source for a long time for melting, thus significantly increasing the risk of damage to the core and the time to form a thin film on the core. Unacceptable for economic reasons.
The desired temperature at which the powder coating material can be processed will, of course, depend on the material from which the tablet core is made, and for some materials the processing step may include temperatures above 250 ° C. In such cases, the exposure time to such high temperatures is reduced.
Preferably, the powder treatment to form the thin film coating includes a heating step, preferably a heating step using infrared radiation, and electromagnetic radiation, electromagnetic conduction, or electromagnetic induction can be used in other forms. The processing of the powder material can be carried out with partial or total pressure reduction around the tablet core. The change in powder material during processing is a simple physical change from solid to liquid and from cooling to a continuous solid film. Recently, powder materials can include polymers that can be cured during processing, such as polymers that cure by gamma radiation, ultraviolet light, or radio frequency energy irradiation to form a crosslinked polymer film.
We have found that the particle size of the powder coating material has a particularly important influence on the behavior of the material in the electrostatic powder coating process. It is advantageous that the particle size of the material is small. It is preferred that at least 95% by volume and at least 90% by volume of the powder material particles have a particle size of 50 μm or less. The term “particle size” refers to the corresponding particle diameter of a particle and can be measured, for example, using laser light diffraction.
Where the relevant particles are composite particles comprising agglomerates or aggregates of particles, the particle size is the size of the composite particles, not the size of individual particles in the agglomerates or aggregates.
Such particle sizes are remarkably small as coating materials for pharmaceutical tablet cores, and in fact, such small particle sizes are recognized as having the drawback of making the materials difficult to manufacture and handle due to their cohesiveness. Has been. However, we have found that the coating of pharmaceutical tablet cores by electrostatic coating methods has particular advantages in adopting small particle sizes and that there are additional advantages by eliminating the drawbacks. For example, the high surface to mass ratio provided by small particles increases the electrostatic force on the particles compared to the inertial force.
Increasing the electrostatic force has the advantage of increasing the force on the particle, which causes the particle to move into contact with the tablet core, while decreasing the inertial force reduces the force required to accelerate the particle and moves backward with the core. Reduces the possibility of particles that bounce and reach the tablet core. We have found that it is particularly advantageous when particles of at least 90% by volume of the powder material have a particle size of 20 μm or less. Preferably, at least 95% by volume of the powder material particles have a particle size of 30 μm or less.
In particular, for selected powder materials, if the particles tend to bounce off the surface of the tablet core, hold the tablet core in close proximity to the powder material source after applying the pretreatment composition to the surface of the tablet core. Let The pretreatment composition was able to improve particle capture by the core surface and enabled the use of large particles as large as 750 μm as the coating material. A liquid can be used in the pretreatment composition to increase the force acting on the particles and keep the particles on the core. When pretreatment is employed, preferably at least 90% by volume of the particles are 300 μm or less in size, and preferably at least 50% by volume of the particles are 200 μm or less in size.
When the particle size becomes very small, the difficulty in handling the powder becomes severe. Thus, it is advantageous that at least 50%, preferably at least 75%, optimally 90% by volume of the powder has a particle size of at least 5 μm.
In one preferred powder coating material, the average particle diameter is about 10 μm and does not include particles having a diameter substantially greater than 100 μm.
Suitably, at least 30% by volume of the powder particles have a particle size in the range of 5 μm to 25 μm.
We have found that it is also particularly important that the powder particles have a narrow range of particle sizes. Preferably at least 30 wt%, more preferably at least 75 wt% of the particles are in the range x to 2x, more preferably in the range x to 1.5x, optimally in the range x to 1.25x. Has a particle size, where x represents the particle size of the powder.
For example, in a powder having relatively small size particles, preferably at least 30% by weight of the particles are in the range of 10 μm to 20 μm, more preferably in the range of 10 μm to 15 μm, optimally in the range of 10 μm to 12.5 μm. Have a particle size of
If the particles are relatively large, for example pretreatment as described above, the preferred relative variation in particle size is usually smaller than for relatively small size particles.
We have found that powders with a large particle size range are disadvantageous compared to powders with a small particle size range for performing a good uniform application of the powder on the tablet core and from core to core. It was. This is thought to be because particles having a certain particle size are preferentially painted on the tablet core when compared to smaller or larger sized particles. This means that there is a difference in the quality of the coating of the core and the change in the quality of the coating, with one painted core painted with a powder material of a newly tailored batch and another painted core coated relatively later in the same batch. It is connected.
Moisture content of powder coating material not more than 10% by weight, preferably not more than 5% by weight, more preferably not more than 3% by weight, based on the weight of the powder coating material (measured by moisture loss during drying) It is convenient to have
There are several different electrostatic effects, and in accordance with the first aspect of the present invention, can be used in electrostatic coating methods using powders to coat pharmaceutical tablet cores, and several different powders that are particularly adapted to the utilization of different effects. Has electrical characteristics. Three different effects and related properties of the powder are described here, and it must be appreciated that each can be used independently of the other or in connection with one or more of the other.
The first possibility is to induce a temporary dipole in the particles of the powder, after which the particles become tablet cores due to the interaction of the dipole with the electric field in the region between the powder source and the tablet core. Led in the direction of. Preferably the coating material is 108-1016Has a specific resistance in the range of Ωm.
A second possibility is to apply a net charge to the powder particles. This net charge is introduced triboelectrically or by corona charging. Therefore, the coating material is preferably receptive to such a net charge and can retain the charge (long enough to guide the material well onto the tablet core).
A third possibility is to give the powder particles a permanent or semi-permanent dipole. Such “electrets” will be directed in the direction of the tablet core by the interaction of the electric field acting on the area between the powder source and the tablet core. Thus, the coating material may include an electret.
A fourth possibility is to provide a magnetic dipole in the powder material using iron or other magnetic material or paramagnetic material.
It is preferred that the powder material can be directed to the tablet core without depending on the overall net charge applied to the powder material and without depending on the permanent implant charge in the powder material. Thus, it is preferred that the powder material be sensitive to movement under the action of electrostatic forces, which sensitivity is measured by the tests specified below.
To determine whether a powder material is sensitive to movement under the influence of electrostatic forces, the following test is performed.
A sample of 0.5 g of powder material is taken and placed on a conductive metal plate placed horizontally and kept at ground potential in an environment with a relative humidity not greater than 65%. This powder material is expanded to a thickness close to a monomolecular layer. After the powder material is left in that state for 30 minutes, a round metal probe with a diameter of 5 mm is placed 10 mm above the center of the powder material, the high voltage is first +10 KV, then -10 KV (current limited to about 5 μA) ) And apply to the probe for about 10 seconds. If the particles of the powder material that represent the material as a whole are attracted upward and contact the probe during either high voltage application, the test results show that the powder material moves under the action of electrostatic force. To be sensitive to. If the particles of the powder material are not attracted upwards and do not contact the probe, or if only certain particles are attracted and the attracted particles are not representative of the material as a whole, the test result is The powder material will not be sensitive to movement under the action of electrostatic forces.
The sensitivity of the powder material naturally depends on the combination of the electrical properties of the powder and other physical properties such as the particle size of the powder.
In order for the particles of the coating material to be charged (eg, triboelectrically) and adhere to the core surface, it is particularly advantageous for the particles to be substantially all of the same symbolic charge. It has been found that an unsatisfactory coating forms on the core surface when a group of particles contains a mixture of positive and negative charges. When the powder is charged, it is preferable that the powder is composed of a composition in which the whole powder has substantially the same symbol charge. Furthermore, if the particles are not of the same symbolic charge, the powder material is oversprayed, reducing the efficiency of the painting process. It is also preferred that most particles have substantially the same charge.
Since the material consists of more than one component, the properties of the powder material can be altered by adjusting the relative proportions of the components. In general, when referring to the properties of a powder material, that property is the property exhibited by the material as a whole, and that one or more components of the material do not exhibit that property alone. . However, it is satisfactory if one or several components of the powder coating material, rather than the powder coating material as a whole, exhibit the following properties: for example, forming a thin film coating at low temperatures The advantages of the material are achieved by only one of the two or more components of the material exhibiting its properties; other components remain solid particles and are larger than particles that convert to a thin film coating. In such a case, there is a substantial variation in the particle sizes of the two components; for example, particles converted to thin film coating have a particle size in the range of 5-20 μm, while solids The particles that remain as particles are substantially larger.
One of the extraneous components may serve to provide the necessary electrostatic properties to the powder material. For example, one extraneous component is triboelectrically and / or coronaally charged and / or becomes an electret or magnet and / or under the action of electrostatic forces as defined in the tests described herein. May be sensitive to movement.
The chemical properties of the powder material are important for the efficiency and appearance of forming the paint.
When discussing the chemical properties of a material, it is advantageous to process a material composed of multiple components, and as will be apparent from the discussion below, the same compound is used as one or more components, and therefore a powder. References in the following description relating to the material consisting of two or more components require that two or more dissimilar components are necessarily present, unless the components are specifically considered different. Should not be considered.
The powder material preferably contains a first component that can be melted at a temperature of 250 ° C. or lower, more preferably 200 ° C. or lower to form a continuous thin film on the core surface. As discussed above, melting can take the form of melting, softening or crosslinking of the first component within the above temperature range.
It is preferred that the first component is substantially soluble in the aqueous medium. Usually, the first component is soluble in a neutral aqueous medium and only dissolves in a selected PH range, such as PH3 to PH6, or PH8 to PH14.
Preferably, the first component consists of polyoxyethylene, sugar alcohol, and one or more of unsaturated or saturated fatty acids and esters. The first component can include a cellulose derivative that melts at a temperature of 250 ° C. or lower, such as hydroxypropylcellulose. Not all cellulose derivatives can be used as the first component, for example hydroxypropylmethylcellulose does not have the required melt properties and carbonizes upon heating.
The first component can include polyethylene glycol, which has good melt properties and can form a good continuous thin film on the substrate surface after processing.
A suitable sugar alcohol is xylitol, which material has suitable electrical properties and melts at a suitable temperature and is useful as a coating material in the coating of pharmaceutical tablet cores.
Other materials that can be used as the first component include waxes and oils, wax or oil alcohols, poloxamers, alkylnaphthalenes such as diethyl phthalate, citric acid and esters. When the powder component is a liquid, the component can simply be added to the other components in liquid form and may be provided with a carrier material, for example in powder form.
Other compounds with suitable melting properties may exist and the above is merely exemplary.
The first component may consist of exactly one compound or may contain two or more compounds.
In many cases, the component with the most desirable melt properties does not provide the optimal electrical properties and / or does not provide the desired finish, coating or appearance of the paint. Therefore, it is preferable to use the second component having the necessary electrical characteristics as described above.
However, it should be understood that the first component may have the desired electrical properties of the second component, and the second component may have the desired melting properties of the first component.
The second component includes acrylic acid, polymers and copolymers of acrylic acid and derivatives thereof such as polymethyl acrylate, polyalkene and derivatives thereof, esters, aryl esters and derivatives thereof, polyvinyl alcohol and esters, cellulose and derivatives thereof such as cellulose It consists of one or more ethers and cellulose esters (crosslinked or non-crosslinked), such as ethyl cellulose, one or more enteric polymers such as cellulose acetate phthalate and hydroxypropyl methylcellulose phthalate. The second component is one of one or more biodegradable polymers such as polylactide, polyglycolide, polyhydroxybutyrate, polyhydroxyvalerate, ethylene vinyl acetate copolymer, and polyanhydride (homo or heteropolymer). One or more may be included. The second component may be polyethylene oxide.
As already mentioned, the first component and the second component may contain the same compound, but in many cases the first and second components are different compounds. For example, the first and second components may each contain xylitol, but in this case a viscosity modifier and a crystallization inhibitor should be added to give the second component the desired melt characteristics.
Preferably, the coating material comprising two or more extraneous components includes a dispersant component that improves the dispersion of the extraneous components. The dispersant component is preferably an anionic, cationic or nonionic surfactant, but may be other compounds which are not usually called surfactants but have similar effects. The dispersant component may be a co-solvent.
The dispersant component may be, for example, one or more of sodium lauryl sulfate, docusate sodium, tween (sorbitan fatty acid ester), poloxamer, and cetostearyl alcohol. Like the first and / or second component compounds, the dispersant component may comprise the same compound. As described above, both the third and first components may include a poloxamer. It is preferred that the material comprises at least 1%, preferably 2-5% by weight of a dispersant component, based on the weight of the material.
It is advantageous for the powder coating material to contain an anti-friction component to reduce frictional forces and / or other forces between the powder coating material particles and improve the flowability of the powder. Anti-friction components include titanium dioxide, colloidal silica, talc or starch, or mixtures thereof.
When the coating material is used in “immediate” release tablets, it is advantageous that the powder coating material includes a disintegrant that can break the coating. In the case of a coating on the tablet core, the inclusion of a disintegrant during coating accelerates the disintegration of the coating immediately when the tablet is ingested.
Disintegrants are those that swell rapidly and strongly when contacted with moisture, thereby destroying the coating. Some disintegrants swell and become 40 times their original volume within seconds. Examples of suitable disintegrants are starch glycolic acid sodium salt (cross-linked) and carboxymethylcellulose sodium salt (cross-linked).
Alternatively or in addition, the disintegrant may be a wicking type, which allows moisture to penetrate through the coating into the tablet core, but prevents back-flow of moisture through the coating from the tablet core and thereby destroys the coating. Examples of suitable wicking type disintegrants are natural starch, cross-linked polyvinyl pyrrolidone (CrossProvidone).
The disintegrant may be a gas generating type such as sodium carbonate, sodium bicarbonate and sodium glycinate.
Preferably, the powder coating material contains up to 10% by volume of disintegrant. Preferably, the powder contains 5 wt% or less, preferably 2 wt% or less, more preferably 1 wt% or less, and optimally about 0.5 wt% disintegrant.
Preferably, the powder coating material further contains one or more opacifiers such as titanium dioxide and talc. Preferably, the material comprises 50 wt% or less, preferably 40 wt% or less, more preferably 30 wt% or less, and most preferably about 10 wt% or less of the opacifier based on the weight of the material.
Preferably, the powder coating material further comprises one or more colorants, such as metal oxides or lakes, such as aluminum lakes, iron oxides, dyes, and one or more taste modifiers, such as aspartame, acesulfame. k, cyclamate, saccharin, sugar, sugar alcohol or flavoring agents, and the like. Preferably, the material comprises 10% by weight or less, preferably 1-5% by weight, based on the weight of the material, and preferably 5% by weight or less, based on the weight of the material. More preferably, it contains 1% by weight or less of a flavoring agent. When the flavoring agent is a sweetener, preferably the material contains 0.5% by weight or less of the sweetener. Preferably, the material comprises 5% by weight or less of colorant and flavor based on the weight of the material. It will be appreciated that the anti-friction component, opacifier, colorant and taste modifier may be the same compound as the other component compounds of the powder coating material.
Powder coating materials can contain bioactive materials, which are materials that increase or decrease process speed in a biological environment. The bioactive material may be a physiologically active material. The coating material containing the active material can be applied, for example, to a tablet core containing the same or different active material, or to a non-active material containing tablet core. The active material can contain one or more compounds. Active materials include acid digestion and exercise inducers, laxatives, antidiarrheals, colon and rectal drugs, pancreatic enzymes and bile acids, antiarrhythmic drugs, antianginal drugs, diuretics, antihypertensive drugs, anticoagulants, anticoagulants Thrombotic drugs, fibrinolytic drugs, hemostatic drugs, fat deficiency drugs, anti-anemic / neutropenic drugs, hypnotics, anti-anxiety drugs, antipsychotic drugs, antidepressants, antiemetics, antispasmodics, CNS stimulants, analgesia Drugs, antipyretic drugs, anti-migraine drugs, non-steroidal anti-inflammatory drugs, anti-ventilants, muscle relaxants, neuromuscular drugs, steroids, hypoglycemia drugs, hyperglycemia drugs, diagnostic drugs, antibiotics, antifungal Drugs, antimalarial drugs, antiviral drugs, immunosuppressive drugs, nutritional drugs, vitamins, electrolytes, appetite suppressants, appetite suppressants, bronchodilators, expectorants, antitussives, mucolytic drugs, decongestants, antiglaucoma Including drugs, oral contraceptives, and / or anti-neoplastic agents.
Tablet cores to which the powder coating material is applied usually contain one or more inert chemicals. Inert chemicals include diluents such as lactose, sucrose, glucose, starch, cellulose, microcrystalline cellulose; binders such as polyvinylpyrrolidone, starch mucus, gelatin, gum arabic; disintegrants such as cross-linked carboxymethylcellulose sodium salt, Sodium starch glycolate, crosslinked polyvinylpyrrolidone; Lubricants such as magnesium stearate, sodium stearyl fumarate; glidants such as colloidal silica, talc; surfactants such as wetting agents, sodium lauryl sulfate, docusate sodium; coloring Agents; can include flavoring agents and / or gas generants such as sodium bicarbonate and citric acid.
The tablet core can also include one or more of the active materials listed above. Preferably, the powder coating material comprises at least 0.5% by weight of active material, more preferably 1% by weight, based on the weight of the powder coating material. For example, a 10 mg coating on a tablet can contain approximately at least 0.05 mg of active material.
The ratio of mixing the components of the powder coating material largely depends on the properties of the material constituting the powder coating material and the substrate to be coated. The ratio is adjusted to achieve the desired electrical and melting characteristics. Usually, the powder coating material contains at least 10%, preferably at least 15%, optimally about 20% by weight of the first component. Usually, the powder coating material contains at least 10% by weight, preferably at least 20% by weight, and more preferably at least 40% by weight of the second component, in each case based on the weight of the powder coating material. Preferably, the weight ratio of the second component to the first component is about 3: 1. The component ratio depends on the materials constituting the first and second components. The ratio is 2: 1 or 1: 1.
The present invention further provides a coating material for electrostatic coating of a pharmaceutical substrate, the coating material containing an active material. As indicated above, the coating material containing the active material is applied to a tablet core containing, for example, the same or different active material, or applied to a core containing an inactive material.
When trying to manage a very small dose of active material in tablet form, the active material is mixed with a large amount of non-active “fill” material to create a manageable size tablet. Traditionally, the active material and the filling material were simply mixed together and the intake of the resulting mixture was tableted. It has been found that accurate management of the amount of active material contained in each tablet is difficult, and the uniformity of intake is insufficient. This was especially observed when the amount of active material required by each tablet was small.
It has been found that by applying the active material to the tablet surface, a very small amount of active material can be accurately applied to the tablet and the reproducibility of the intake can be improved.
The amount of active material contained in the coating material will of course depend on the amount of active material intake applied to the substrate and the thickness of the coating formed. Usually, the material contains at least 0.5% by weight of active material, based on the weight of the coating.
Conveniently, the coating material is a powder coating material. It is therefore convenient to apply the coating material using a method similar to that described above, and the coating material is applied to the substrate accurately and without overspraying.
Preferably, the coating material containing the active material contains at least 90% by volume of particles having a particle size not greater than 50 μm. Preferably, at least 90% by volume of the powder particles have a particle size of 30 μm or less, more preferably 20 μm or less.
The present invention also provides the use of a coating material comprising an active material in electrostatic coating of a substrate, particularly in the electrostatic coating of a pharmaceutical tablet core.
The first aspect of the present invention also provides a method of electrostatically coating a pharmaceutical tablet core with a powder material, and a powder material as defined above.
Furthermore, the 1st viewpoint of this invention provides the powder coating material for electrostatic coating of a base material, and a powder is obtained by the above methods.
Still further, a first aspect of the present invention provides a pharmaceutical tablet comprising a tablet core and a powder coating material as defined above.
Furthermore, a first aspect of the present invention provides a method of coating a pharmaceutical tablet core with powder, the method holding the tablet core in proximity to a source of powder coating material in an electric field, and at least the core. This portion is held at a potential different from the potential of the coating material, and a potential difference is applied to guide the powder from the powder source in the direction of the tablet core and the core surface, and the powder coating material is applied.
Since the coating of the tablet core induces the powder material towards the tablet core as a result of the application of an electric field and at least the potential difference between the tablet core portion and the powder material, the point of arrival of the powder material is at least initially the tablet. Limited to the surface of the wick. If it is arranged only on the exposed surface, it is in the vicinity of the powder material and where there is an appropriate potential difference with respect to the powder material.
A special advancement of the method is that it can be carried out in a continuous process.
It is advantageous to transfer the tablet core by transfer means through an area proximate to the source of powder coating material. By transferring the tablet core, it can be ensured that the tablet core is handled gently throughout the coating process and that even the fragile tablet core is not damaged.
This method can be used to coat tablet cores that are fragile and cannot withstand conventional tablet coating methods. Thus, the present invention has made it possible to produce tablets having a conventional shape and having a wide range of compositions. Also, unconventional shaped tablets, for example, tablets that are not conventional circular surfaces but rather have opposite planes can be produced by the method of the present invention. Such flat tablets are usually very fragile and could not be painted by conventional methods. Furthermore, plane tablets are often joined together to form twin tablets and groups of tablets, which could not be properly painted by conventional coating methods.
The tablet core is held from the top close to the powder coating material source and the powder moves from above the source to the lower surface of the substrate.
The tablet core produced by the coating method specified above is simply a partial coating, and this coating method includes the following further steps, which are applied in the vicinity of the powder coating material source in an electric field. Holding the tablet core, maintaining at least a portion of the tablet core at a potential different from the potential of the coating material, applying a potential difference to direct the powder from the powder source toward the tablet core, and uncovering the uncoated surface of the tablet core It is to be painted with powder coating material. In this way, it is possible to easily apply to the entire surface of the tablet core, and it is also possible to apply different parts of the tablet core with different coating materials. For example, different colors can be applied to each opposite side of the tablet.
Furthermore, the 1st viewpoint of this invention provides the pharmaceutical tablet which gave electrostatic coating by the method specified above.
In accordance with the first aspect of the present invention, powder coating materials and coating methods have been developed, especially for pharmaceutical tablet core coatings and to address the harsh conditions that can be imposed on the material from the application of the coating. Although materials and methods have been developed that are suitable for pharmaceutical tablet core coatings, we have further expanded our thinking to other uses where the materials and methods can be used effectively. For example, in the pharmaceutical industry, the materials and methods can be used to paint other pharmaceutical products that are not taken orally, for example, pessaries, boogies or suppositories, or other pharmaceutical substrates.
According to a second aspect of the present invention, there is provided a powder coating material for electrostatic powder coating of a pharmaceutical substrate, the material having one or more of the following properties.
a) suitable for human and / or animal consumption;
b) consisting of at least two foreign components, preferably the particles consist of composite particles,
c) A thin film coating is formed by melting at a temperature of 250 ° C. or less at atmospheric pressure.
d) at least 30% by weight of the particles have a particle size ranging from 5 μm to 20 μm,
e) It is sensitive to movement under the action of electrostatic force, and its sensitivity is measured by the test method specified here.
It is particularly preferred that the powder coating material is a physiologically acceptable material and preferably a pharmaceutically acceptable material. The material can have other properties as described above in the description of the pharmaceutical tablet core coating material.
The present invention also provides a method for producing a powder coating material comprising at least two extraneous components for electrostatic coating of a substrate, the method comprising the step of simultaneously treating the at least two extraneous components. It is a waste.
Furthermore, the second aspect of the present invention provides a method of electrostatically coating a pharmaceutical substrate with the powder coating material specified above.
Here, when there is a description relating to a number% of particles having a specific size, such as a number% of particles, it is preferable that the particles have the same volume% of the particles of the size. Furthermore, when there is a description about the volume% particles, it is preferred that the particles have the same weight% particles.
By way of example, a method for coating a pharmaceutical tablet core and several powder coating materials suitable for coating a pharmaceutical tablet core will be described with reference to the accompanying drawings.
In the drawings, FIG. 1 schematically shows a side view of an apparatus for coating a tablet core, and FIG. 2 schematically shows a cross section of a drum of the apparatus of FIG.
The apparatus schematically illustrated in FIG. 1 is an apparatus for coating both sides of a pharmaceutical tablet core. The apparatus includes an inclined chute for supplying a tablet core that is connected to the first
The
The
The tablet core collecting chute 22 is inclined downwardly away from the second drum 12 'downstream of the melting position C', and the coated tablet core is taken out and connected to the next processing and packaging process.
The
Each indentation 14 on the drum is provided with an
The grounded fixed arched
The
In use, the lead is continuously supplied to the
The
The
As the
The drum itself is preferably at least 60 mm in diameter and not less than the minimum tablet diameter in width and rotates at least 1/2 rpm. The suction pressure of the suction connecting pipe is of a size effective for holding the tablet against gravity, and is preferably 0.2 to 0.6 bar under atmospheric pressure.
In the
At the coating positions B and B ', the powder coating material is supplied to the
In melting or drying positions C and C ', energy is applied to the core surface to melt the powder and provide a uniform coating on the exposed surface of the core. Preferably, the energy is provided by focused irradiation in the infrared region. Energy performance requirements are largely determined by the coating material. After melting or drying, the coating is fixed in a cooling process using a blower.
A preferred coating device according to the present invention is capable of painting up to 300,000 tablet cores per hour.
Examples of powder coating materials suitable for use in the tablet core coating method described above with reference to FIGS. 1 and 2 are described below.
Example 1
The dry powder coating material was prepared by the following method.
(A) Samples containing the following compounds (wt%) were pre-mixed using a high shear mixer.
55.5% Udolite RS ™ (ammonio-methacrylate copolymer fine powder)
18.5% polyethylene glycol (high molecular weight: about 20000)
15.0% titanium dioxide
5.0% aluminum rake
5.0% sodium lauryl sulfate
0.5% Exprotab ™ (starch glycolate sodium salt)
0.5% Aerosil 200 ™ (colloidal silicon dioxide)
Prior to mixing, the particle size of each component of the sample was as follows.
Titanium dioxide 50% by volume is 5μm or less
Aluminum lake 50% by volume is less than 1μm
Sodium lauryl sulfate 50% by volume is 100μm or less
Eudolite 50% by volume is 40μm or less
Polyethylene glycol 50% by volume is 60 to 70 μm
(B) The previous mixture was wet granulated by the following method. Water was gradually added to the mixture obtained in (a) above and mixed for several minutes in a high shear mixer to obtain a granular mixture. The weight of the added water was about 10-15% of the premix weight.
(C) The granular mixture obtained in step (b) above is dried in a fluid bed dryer at a temperature of about 45 ° C. for about 20-30 minutes to a moisture content of 3% by weight or less (as drying loss) A material having (measurement) was obtained.
(D) The small particles obtained in step (c) were impact pulverized and then finely pulverized using a fluid energy pulverizer to obtain a powder. The powder had a size of 50% by volume of particles of 20 μm or less and almost 100% by volume of 60 μm or less. The peak of the particle size distribution was observed at about 10 μm.
The powder was sensitive to movement under the action of the electrostatic force specified above.
(E) A tablet core was coated with the powder using the method and apparatus described previously. No pretreatment with the trapping power enhancing liquid was performed. The coating powder on the tablet core was heated to a temperature of about 130 ° C. for about 5 seconds using an infrared source to melt the powder coating on the tablet core surface. The resulting coating had good opacity, was smooth, glossy and brightly colored. The coating thickness was 100 μm or less.
The particle size distribution of the powder particles prepared in the step (d) was measured.
100% 57.25 μm or less
70.29% 22.04 μm or less
5.58% 1.52 μm or less
About 50% of the particles were 15.05 μm to 32.29 μm in size.
About 35% of the particles were 18.21 μm to 32.29 μm size.
The average particle size was 19.17 μm (calculated in one way).
Example 2
Using a sample containing the following compound (% by weight)
59.6% Eudolite RS (ammonio-methacrylate copolymer)
19.9% Crucell ™ (hydroxypropyl cell sauce)
15.0% titanium dioxide
5.0% aluminum rake
0.5% croscarmellose sodium (cross-linked sodium carboxymethyl cellulose)
A powder coating material was prepared by the method described in steps (a) to (d) of Example 1. As described in step (e) of Example 1, the powder material was applied to the tablet core surface and melted. The resulting coating was smooth, highly glossy, had a strong color and good opacity. This coating was judged to have a higher gloss than that expected for a conventional thin film-coated tablet core.
Example 3
Using a sample containing the following compound (% by weight)
39.75% Eudolite RS (ammonio methacrylate copolymer)
39.75% Crucell (hydroxypropyl cell sauce)
15.0% titanium dioxide
5.0% aluminum rake
0.5% Aerosil 200 (colloidal silicon dioxide)
A powder coating material was prepared by the method described in steps (a) to (d) of Example 1. As described in step (e) of Example 1, the powder material was applied to the tablet core surface and melted. The resulting coating was smooth, glossy, had a strong color and good opacity.
Example 4
Using a sample containing the following compound (% by weight)
60.0% Eudolite RS (ammonio methacrylate copolymer)
20.0% Glycerol monostearate
15.0% titanium dioxide
5.0% aluminum rake
A powder coating material was prepared by the method described in steps (a) to (d) of Example 1. As described in step (e) of Example 1, the powder material was applied to the tablet core surface and melted. The resulting coating was smooth, matte, had a strong color and good opacity.
Example 5
Using a sample containing the following compound (% by weight)
60.0% Eudolite RS (ammonio methacrylate copolymer)
20.0% Xylitol
15.0% titanium dioxide
5.0% aluminum rake
A powder coating material was prepared by the method described in steps (a) to (d) of Example 1. As described in step (e) of Example 1, the powder material was applied to the tablet core surface and melted. The resulting coating was semi-gloss, had a strong color and good opacity.
Example 6
Using a sample containing the following compound (% by weight)
46.5% Eudolite RS (ammonio methacrylate copolymer)
28.0% Crucell (hydroxypropyl cell sauce)
15.0% titanium dioxide
5.0% aluminum rake
5.0% polyethylene glycol 6000
0.5% Aerosil 200 (colloidal silicon dioxide)
A powder coating material was prepared by the method described in steps (a) to (d) of Example 1. As described in step (e) of Example 1, the powder material was applied to the tablet core surface and melted. The resulting coating was smooth, had a strong color and good opacity.
Example 7
A sample containing the following compound (% by weight)
56.25% polyethylene glycol
20.0% Titanium dioxide
18.75% Eudolite RS (ammonio methacrylate copolymer)
5.0% aluminum rake
Formulated using a high shear mixer. In the pre-formulation state, polyethylene glycol and eudolite are at least 50% by volume of particles having a size of 100-200 μm and similar particle sizes, and at least 50% by volume of titanium dioxide and aluminum lake are less than 1 μm. Had a size.
(B) The dried blended mixture was pulverized to obtain a powder material having a particle size of 300 μm or less in which at least 50% by volume of the particles had a size of 100 to 200 μm.
(C) The material was applied to the tablet core using the method and apparatus described above, including a pretreatment spray of polyethylene glycol. The coating powder on the tablet core was heated to a temperature of about 130 ° C. for about 5 seconds using an infrared source to melt the powder coating on the tablet core surface. The resulting coating was smooth, high gloss, strong color and good opacity. This coating was judged to have a higher gloss than that expected for a conventional thin film-coated tablet core.
Example 8
A sample containing the following compound (% by weight)
56.25% polyethylene glycol
20.0% Titanium dioxide
18.75% Eudolite RS (ammonio methacrylate copolymer)
5.0% aluminum rake
Dry blended using a high shear mixer and the blended mixture was milled as described in Example 7, step (b). In addition, the said component had the particle size similar to the particle size as described in Example 7 before the preparation (polyethylene glycol has the same particle size as that of Udrite). The resulting material was applied to the tablet core as described in step (c) of Example 7. The resulting coating was smooth, high gloss, strong color and good opacity. This coating was judged to have a higher gloss than that expected for a conventional thin film-coated tablet core.
In the above embodiment, all the components are in the form of a particulate solid material, but the powder coating material may contain a liquid-shaped component.
Claims (39)
前記第1成分は、250℃以下の温度で溶融して基材表面に連続薄膜を形成し、ポリオキシエチレン、糖アルコール、不飽和または飽和脂肪酸またはそのエステル、セルロース誘導体、ポリエチレングリコール、ワックスまたはオイル、ワックスまたはオイルのアルコール、ポロクサマー、アルキルフタレート、クエン酸またはそのエステルから成る群から選択される1以上の化合物を含み、
前記第2成分は、粉末材料に静電気特性を付与し、アクリル酸、アクリル酸のポリマーとコポリマーおよびその誘導体、ポリアルケンとその誘導体、ポリビニルアルコールとエステル、セルロースとその誘導体、ポリラクチド、ポリグリコリド、ポリヒドロキシブチレート、ポリヒドロキシバレレート、エチレンビニルアセテートコポリマー、ポリ酸無水物、ポリエチレンオキシドから成る群から選択される1以上の化合物を含み、
基材を前記粉末材料で被覆した後、前記粉末材料を溶融し、基材に固定した連続薄膜を形成する、前記方法。A method of electrostatically coating a pharmaceutical substrate with a powder material, wherein the powder material is pharmaceutically acceptable and contains composite particles, each composite particle having a first component having different physical and / or chemical properties And at least a second component,
The first component is melted at a temperature of 250 ° C. or lower to form a continuous thin film on the surface of the substrate, and polyoxyethylene, sugar alcohol, unsaturated or saturated fatty acid or ester thereof, cellulose derivative, polyethylene glycol, wax or oil. One or more compounds selected from the group consisting of alcohols of waxes or oils, poloxamers, alkyl phthalates, citric acid or esters thereof,
The second component imparts electrostatic properties to the powder material, and includes acrylic acid, polymers and copolymers of acrylic acid and derivatives thereof, polyalkene and derivatives thereof, polyvinyl alcohol and esters, cellulose and derivatives thereof, polylactide, polyglycolide, polyhydroxy Including one or more compounds selected from the group consisting of butyrate, polyhydroxyvalerate, ethylene vinyl acetate copolymer, polyanhydride, polyethylene oxide,
The method, wherein after coating a base material with the powder material, the powder material is melted to form a continuous thin film fixed to the base material.
前記第1成分は、250℃以下の温度で溶融して基材表面に連続薄膜を形成し、ポリオキシエチレン、糖アルコール、不飽和または飽和脂肪酸またはそのエステル、セルロース誘導体、ポリエチレングリコール、ワックスまたはオイル、ワックスまたはオイルのアルコール、ポロクサマー、アルキルフタレート、クエン酸またはそのエステルから成る群から選択される1以上の化合物を含み、
前記第2成分は、粉末材料に静電気特性を付与し、アクリル酸、アクリル酸のポリマーとコポリマーおよびその誘導体、ポリアルケンとその誘導体、ポリビニルアルコールとエステル、セルロースとその誘導体、ポリラクチド、ポリグリコリド、ポリヒドロキシブチレート、ポリヒドロキシバレレート、エチレンビニルアセテートコポリマー、ポリ酸無水物、ポリエチレンオキシドから成る群から選択される1以上の化合物を含み、
粉末の粒子の少なくとも30容量%が5μm〜25μmの範囲の粒子サイズを有する粉末塗装材料の医薬基材静電塗装における使用。 Medical drug to unacceptable treatment by can form a thin film coating and includes composite particles, each composite particle comprises at least a first component and a second component having different physical and / or chemical properties,
The first component is melted at a temperature of 250 ° C. or lower to form a continuous thin film on the surface of the substrate, and polyoxyethylene, sugar alcohol, unsaturated or saturated fatty acid or ester thereof, cellulose derivative, polyethylene glycol, wax or oil. One or more compounds selected from the group consisting of alcohols of waxes or oils, poloxamers, alkyl phthalates, citric acid or esters thereof,
The second component imparts electrostatic properties to the powder material, and includes acrylic acid, polymers and copolymers of acrylic acid and derivatives thereof, polyalkene and derivatives thereof, polyvinyl alcohol and esters, cellulose and derivatives thereof, polylactide, polyglycolide, polyhydroxy Including one or more compounds selected from the group consisting of butyrate, polyhydroxyvalerate, ethylene vinyl acetate copolymer, polyanhydride, polyethylene oxide,
Use of a powder coating material in a pharmaceutical substrate electrostatic coating, wherein at least 30% by volume of the particles of the powder have a particle size in the range of 5 to 25 μm.
前記第1成分は、250℃以下の温度で溶融して基材表面に連続薄膜を形成し、ポリオキシエチレン、糖アルコール、不飽和または飽和脂肪酸またはそのエステル、セルロース誘導体、ポリエチレングリコール、ワックスまたはオイル、ワックスまたはオイルのアルコール、ポロクサマー、アルキルフタレート、クエン酸またはそのエステルから成る群から選択される1以上の化合物を含み、
前記第2成分は、粉末材料に静電気特性を付与し、アクリル酸、アクリル酸のポリマーとコポリマーおよびその誘導体、ポリアルケンとその誘導体、ポリビニルアルコールとエステル、セルロースとその誘導体、ポリラクチド、ポリグリコリド、ポリヒドロキシブチレート、ポリヒドロキシバレレート、エチレンビニルアセテートコポリマー、ポリ酸無水物、ポリエチレンオキシドから成る群から選択される1以上の化合物を含み、
前記材料が活性材料をも含む粉末塗装材料の医薬基材の静電塗装における使用。 Medical drug to unacceptable treatment by can form a thin film coating and includes composite particles, each composite particle comprises at least a first component and a second component having different physical and / or chemical properties,
The first component is melted at a temperature of 250 ° C. or lower to form a continuous thin film on the surface of the substrate, and polyoxyethylene, sugar alcohol, unsaturated or saturated fatty acid or ester thereof, cellulose derivative, polyethylene glycol, wax or oil. One or more compounds selected from the group consisting of alcohols of waxes or oils, poloxamers, alkyl phthalates, citric acid or esters thereof,
The second component imparts electrostatic properties to the powder material, and includes acrylic acid, polymers and copolymers of acrylic acid and derivatives thereof, polyalkene and derivatives thereof, polyvinyl alcohol and esters, cellulose and derivatives thereof, polylactide, polyglycolide, polyhydroxy Including one or more compounds selected from the group consisting of butyrate, polyhydroxyvalerate, ethylene vinyl acetate copolymer, polyanhydride, polyethylene oxide,
Use of a powder coating material in which the material also comprises an active material in electrostatic coating of a pharmaceutical substrate .
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9509347.2 | 1995-05-09 | ||
GBGB9509347.2A GB9509347D0 (en) | 1995-05-09 | 1995-05-09 | Electrostatic coating |
GB9520302.2 | 1995-10-05 | ||
GBGB9520302.2A GB9520302D0 (en) | 1995-10-05 | 1995-10-05 | Improvements in or relating to electrostatic coating of substrates |
PCT/GB1996/001101 WO1996035413A1 (en) | 1995-05-09 | 1996-05-08 | Powder coating composition for electrostatic coating of pharmaceutical substrates |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11505530A JPH11505530A (en) | 1999-05-21 |
JP4137998B2 true JP4137998B2 (en) | 2008-08-20 |
Family
ID=26307004
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8533866A Pending JPH11507292A (en) | 1995-05-09 | 1996-05-08 | Electrostatic painting |
JP53386596A Expired - Fee Related JP4137998B2 (en) | 1995-05-09 | 1996-05-08 | Powder coating composition for electrostatic coating of pharmaceutical substrates |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP8533866A Pending JPH11507292A (en) | 1995-05-09 | 1996-05-08 | Electrostatic painting |
Country Status (19)
Country | Link |
---|---|
US (4) | US6406738B1 (en) |
EP (3) | EP0824344B1 (en) |
JP (2) | JPH11507292A (en) |
KR (2) | KR19990008431A (en) |
CN (2) | CN1183738A (en) |
AT (2) | ATE293440T1 (en) |
AU (2) | AU5655196A (en) |
BR (2) | BR9608208A (en) |
CA (1) | CA2220506C (en) |
CZ (2) | CZ352197A3 (en) |
DE (2) | DE69634631T2 (en) |
DK (2) | DK0824344T3 (en) |
ES (2) | ES2194100T3 (en) |
HU (1) | HUP9901981A3 (en) |
NO (2) | NO975132L (en) |
PL (2) | PL323315A1 (en) |
PT (2) | PT824344E (en) |
TR (2) | TR199701324T1 (en) |
WO (2) | WO1996035516A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08244678A (en) * | 1995-03-10 | 1996-09-24 | Shinkurushima Dock:Kk | Tank barge type liquid cargo transport ship |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE293440T1 (en) * | 1995-05-09 | 2005-05-15 | Phoqus Pharmaceuticals Ltd | POWDER COATING COMPOSITION FOR ELECTROSTATIC COATING OF PHARMACEUTICAL SUBSTRATES |
US7008668B2 (en) | 1995-05-09 | 2006-03-07 | Phoqus Pharmaceuticals Limited | Powder coating composition for electrostatic coating of pharmaceutical substrates |
US5714007A (en) * | 1995-06-06 | 1998-02-03 | David Sarnoff Research Center, Inc. | Apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate |
US5789014A (en) * | 1995-12-25 | 1998-08-04 | Shin-Etsu Chemical Co., Ltd. | Method of manufacturing a solid preparation coated with non-solvent coating |
GB9623634D0 (en) | 1996-11-13 | 1997-01-08 | Bpsi Holdings Inc | Method and apparatus for the coating of substrates for pharmaceutical use |
DE19809719A1 (en) | 1998-03-06 | 1999-09-09 | Roehm Gmbh | Aqueous dispersion for binder and coating for medicine |
US6498135B1 (en) * | 1998-04-06 | 2002-12-24 | Procter & Gamble Company | Process for producing electrostatically coated non-particulate detergent product |
US6652903B2 (en) | 1998-07-09 | 2003-11-25 | Lts Lohmann Therapie-Systeme Ag | Dry-copying method for producing flat, individually dosed preparations of active agents |
DE19830650C1 (en) * | 1998-07-09 | 1999-08-12 | Lohmann Therapie Syst Lts | Dry copying to give bonded active ingredients at a substrate surface for transdermal therapy |
US6372246B1 (en) * | 1998-12-16 | 2002-04-16 | Ortho-Mcneil Pharmaceutical, Inc. | Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals |
US6806017B2 (en) | 1999-12-17 | 2004-10-19 | Phoqus Limited | Electrostatic application of powder material to solid dosage forms |
GB9929946D0 (en) | 1999-12-17 | 2000-02-09 | Phoqus Limited | Electrostatic application of powder material to solid dosage forms |
GB0002305D0 (en) * | 2000-02-01 | 2000-03-22 | Phoqus Limited | Power material for electrostatic application |
KR100721088B1 (en) * | 2000-04-26 | 2007-05-23 | 신에쓰 가가꾸 고교 가부시끼가이샤 | Solid Formulation Coated by Film Coating Layer And Film Coating Agent |
KR100949539B1 (en) | 2000-06-27 | 2010-03-25 | 벡투라 리미티드 | Method of making particles for use in a pharmaceutical composition |
GB2370243B (en) | 2000-12-21 | 2004-06-16 | Phoqus Ltd | Electrostatic application of powder material to solid dosage forms in an elect ric field |
CA2450361A1 (en) * | 2001-06-26 | 2003-01-09 | Tiger Microsystems, Inc. | Dry powder electrostatic deposition method and apparatus |
GB0117619D0 (en) * | 2001-07-19 | 2001-09-12 | Phoqus Ltd | Pharmaceutical dosage form |
GB0117618D0 (en) * | 2001-07-19 | 2001-09-12 | Phoqus Ltd | Pharmaceutical dosage form |
US7217381B2 (en) | 2001-09-28 | 2007-05-15 | Mcneil-Ppc, Inc. | Systems, methods and apparatuses for manufacturing dosage forms |
US7838026B2 (en) | 2001-09-28 | 2010-11-23 | Mcneil-Ppc, Inc. | Burst-release polymer composition and dosage forms comprising the same |
US6982094B2 (en) | 2001-09-28 | 2006-01-03 | Mcneil-Ppc, Inc. | Systems, methods and apparatuses for manufacturing dosage forms |
US6767200B2 (en) | 2001-09-28 | 2004-07-27 | Mcneil-Ppc, Inc. | Systems, methods and apparatuses for manufacturing dosage forms |
US6742646B2 (en) | 2001-09-28 | 2004-06-01 | Mcneil-Ppc, Inc. | Systems, methods and apparatuses for manufacturing dosage forms |
US7323192B2 (en) * | 2001-09-28 | 2008-01-29 | Mcneil-Ppc, Inc. | Immediate release tablet |
US6837696B2 (en) * | 2001-09-28 | 2005-01-04 | Mcneil-Ppc, Inc. | Apparatus for manufacturing dosage forms |
CN1596101A (en) | 2001-09-28 | 2005-03-16 | 麦克内尔-Ppc股份有限公司 | Fondant composition contained dosage forms |
US7122143B2 (en) | 2001-09-28 | 2006-10-17 | Mcneil-Ppc, Inc. | Methods for manufacturing dosage forms |
GB2384199B (en) | 2002-01-17 | 2005-04-06 | Phoqus Ltd | Electrostatic application of powder material to solid dosage forms |
US7169450B2 (en) | 2002-05-15 | 2007-01-30 | Mcneil-Ppc, Inc. | Enrobed core |
US6946156B2 (en) * | 2002-05-15 | 2005-09-20 | Mcneil-Ppc, Inc. | Process for enrobing a core |
GB0221293D0 (en) | 2002-09-13 | 2002-10-23 | Phoqus Ltd | Method and apparatus for applying powder in a pattern to a substrate |
US7807197B2 (en) * | 2002-09-28 | 2010-10-05 | Mcneil-Ppc, Inc. | Composite dosage forms having an inlaid portion |
GB2402895B (en) * | 2003-06-18 | 2006-08-23 | Phoqus Pharmaceuticals Ltd | Method and apparatus for the application of powder material to substrates |
GB0314832D0 (en) * | 2003-06-25 | 2003-07-30 | Phoqus Pharmaceuticals Ltd | Production of capsule shells and capsules |
US20040265504A1 (en) * | 2003-06-27 | 2004-12-30 | Christophe Magnin | Non-metalic substrate having an electostatically applied activatable powder adhesive |
US7198675B2 (en) | 2003-09-30 | 2007-04-03 | Advanced Cardiovascular Systems | Stent mandrel fixture and method for selectively coating surfaces of a stent |
US20050074514A1 (en) * | 2003-10-02 | 2005-04-07 | Anderson Oliver B. | Zero cycle molding systems, methods and apparatuses for manufacturing dosage forms |
CA2547594A1 (en) * | 2003-12-01 | 2005-06-16 | Takeda Pharmaceutical Company Limited | Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing |
GB0330171D0 (en) * | 2003-12-30 | 2004-02-04 | Phoqus Pharmaceuticals Ltd | Method and apparatus for the application of powder material to substrates |
GB0407312D0 (en) * | 2004-03-31 | 2004-05-05 | Phoqus Pharmaceuticals Ltd | Method and apparatus for the application of powder material to substrates |
US7553377B1 (en) | 2004-04-27 | 2009-06-30 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for electrostatic coating of an abluminal stent surface |
GB0409381D0 (en) | 2004-04-27 | 2004-06-02 | Phoqus Pharmaceuticals Ltd | Electrostatic application of powder materials to solid dosage forms |
WO2005115340A1 (en) * | 2004-05-19 | 2005-12-08 | Glatt Air Techniques, Inc. | Micropellet containing pellets and method of preparing such pellets |
US7390524B1 (en) | 2004-05-20 | 2008-06-24 | Advanced Cardiovascular Systems, Inc. | Method for electrostatic spraying of an abluminal stent surface |
US20060002986A1 (en) * | 2004-06-09 | 2006-01-05 | Smithkline Beecham Corporation | Pharmaceutical product |
TWI428271B (en) * | 2004-06-09 | 2014-03-01 | Smithkline Beecham Corp | Apparatus and method for pharmaceutical production |
US8101244B2 (en) * | 2004-06-09 | 2012-01-24 | Smithkline Beecham Corporation | Apparatus and method for producing or processing a product or sample |
US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
EP1912614A4 (en) * | 2005-08-03 | 2009-08-05 | Univ Western Ontario | Direct coating solid dosage forms using powdered materials |
GB0522188D0 (en) * | 2005-10-31 | 2005-12-07 | Bioprogress Technology Ltd | Apparatus for tablet coating |
US7867547B2 (en) | 2005-12-19 | 2011-01-11 | Advanced Cardiovascular Systems, Inc. | Selectively coating luminal surfaces of stents |
US8003156B2 (en) | 2006-05-04 | 2011-08-23 | Advanced Cardiovascular Systems, Inc. | Rotatable support elements for stents |
RU2438354C2 (en) * | 2006-05-12 | 2012-01-10 | Марс Инкорпорейтед | Food toner |
AU2007249341B2 (en) | 2006-05-12 | 2012-02-02 | Mars, Incorporated | Use of powders for creating images on objects, webs or sheets |
US8603530B2 (en) | 2006-06-14 | 2013-12-10 | Abbott Cardiovascular Systems Inc. | Nanoshell therapy |
US8048448B2 (en) | 2006-06-15 | 2011-11-01 | Abbott Cardiovascular Systems Inc. | Nanoshells for drug delivery |
US8017237B2 (en) | 2006-06-23 | 2011-09-13 | Abbott Cardiovascular Systems, Inc. | Nanoshells on polymers |
US7976872B2 (en) * | 2006-07-24 | 2011-07-12 | L. Perrigo Company | Method for distributing a pharmaceutically active compound in an excipient |
CN101553359B (en) * | 2006-10-19 | 2014-04-16 | 阿肯色大学董事会 | Methods and apparatus for making coatings using electrostatic spray |
EP2138166A4 (en) * | 2007-04-26 | 2012-11-21 | Eisai R&D Man Co Ltd | Process for production of tablet |
US8048441B2 (en) | 2007-06-25 | 2011-11-01 | Abbott Cardiovascular Systems, Inc. | Nanobead releasing medical devices |
EP2045319B8 (en) | 2007-09-19 | 2016-02-24 | Dalli-Werke GmbH & Co. KG | Coated detergent composition and manufacture process |
EP2394746A1 (en) * | 2010-06-14 | 2011-12-14 | Saint-Gobain Glass France | Method for flood coating a polymeric material |
EA201300982A1 (en) | 2011-03-03 | 2014-02-28 | Мерк Патент Гмбх | HARD PHARMACEUTICAL PREPARATION COATED |
ES2891092T3 (en) | 2011-03-11 | 2022-01-26 | Intercontinental Great Brands Llc | Multi-layer confectionery product forming method |
WO2012149326A1 (en) | 2011-04-29 | 2012-11-01 | Massachusetts Institute Of Technology | Layer processing for pharmaceuticals |
CN102851304A (en) * | 2011-06-30 | 2013-01-02 | 复旦大学 | Electrostatic coating based non-viral nucleic acid ternary complex system and preparation method thereof |
CN108925737A (en) | 2011-07-21 | 2018-12-04 | 洲际大品牌有限责任公司 | Systems and methods for forming and cooling chewing gum |
US9693962B2 (en) * | 2012-06-05 | 2017-07-04 | Takeda Pharmaceutical Limited | Dry-coated tablet |
WO2015021445A1 (en) | 2013-08-09 | 2015-02-12 | Perceptimed, Inc. | Pill feeder |
US10334867B2 (en) | 2014-03-03 | 2019-07-02 | Intercontinental Great Brands Llc | Method for manufacturing a comestible |
US10213960B2 (en) | 2014-05-20 | 2019-02-26 | Massachusetts Institute Of Technology | Plasticity induced bonding |
CN104396381A (en) * | 2014-12-08 | 2015-03-11 | 孙永国 | Seed coating machine and seed coating method |
US20160370253A1 (en) * | 2015-06-19 | 2016-12-22 | Sanyasi R. Kalidindi | Powder segregation testing apparatus and method of using |
CN108367078A (en) * | 2016-10-19 | 2018-08-03 | 宁波西敦医药包衣科技有限公司 | The dry powder coated composition of medical pellet |
CN107028765A (en) * | 2017-05-05 | 2017-08-11 | 盐城卫生职业技术学院 | Pharmaceutical process plant and drug handling device |
US11022987B2 (en) * | 2017-07-21 | 2021-06-01 | Carlisle Fluid Technologies, Inc. | Systems and methods for improved control of impingement mixing |
US20190159508A1 (en) * | 2017-11-29 | 2019-05-30 | Frito-Lay North America, Inc. | Method of Coating Food Products |
CN108926484A (en) * | 2018-07-27 | 2018-12-04 | 宁波西敦医药包衣科技有限公司 | Dry powder seed-coating machine |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US433076A (en) * | 1890-07-29 | Spring-motor | ||
US432449A (en) * | 1890-07-15 | Sewing-machine | ||
DE52460C (en) | F. BlNELLI in Rom | Lifting device for sunken ships | ||
FR24084E (en) | 1920-03-13 | 1922-02-21 | Capon Nee Antoine Rousset | Extendable mannequin |
US2698814A (en) | 1952-05-01 | 1955-01-04 | Ransburg Electro Coating Corp | Electrostatic coating apparatus and method |
NL6406815A (en) * | 1963-06-19 | 1964-12-21 | ||
GB1108791A (en) | 1964-04-06 | 1968-04-03 | Addressograph Multigraph | Electrophotographic developer mixes |
DE1617282A1 (en) | 1965-11-30 | 1975-02-06 | Astra Pharma Prod | DEVICE FOR LOCAL ANESTHETIZATION BY LOCAL APPLICATION AND METHOD FOR MANUFACTURING THIS DEVICE |
DE2247701A1 (en) * | 1972-09-28 | 1974-04-11 | Heinz Dr Haase | METHOD AND DEVICE FOR APPLYING SOLID OR LIQUID PARTICLES TO SURFACES BY USING ELECTRIC FIELD FORCE |
US3900000A (en) * | 1973-11-28 | 1975-08-19 | Thomas J Gallen | Apparatus for spray coating articles |
DE3049179A1 (en) | 1975-03-20 | 1982-07-29 | Röhm GmbH, 6100 Darmstadt | Using vinyl! copolymer as binding agent for pharmaceutical dosages - prepd. by dispersing the copolymer spray-dried powder in softening soln. |
CH624846A5 (en) | 1975-12-15 | 1981-08-31 | Hoffmann La Roche | Solid pharmaceutical unit dose form and process and apparatus for producing it |
US4349531A (en) * | 1975-12-15 | 1982-09-14 | Hoffmann-La Roche Inc. | Novel dosage form |
US4029757A (en) * | 1975-12-15 | 1977-06-14 | Hoffmann-La Roche Inc. | Manufacture of pharmaceutical unit dosage forms |
US4197289A (en) | 1975-12-15 | 1980-04-08 | Hoffmann-La Roche Inc. | Novel dosage forms |
AU514195B2 (en) | 1975-12-15 | 1981-01-29 | F. Hoffmann-La Roche & Co. | Dosage form |
US4427712A (en) * | 1976-04-13 | 1984-01-24 | Continental Can Company, Inc. | Electrodynamic coating process |
JPS52151717A (en) | 1976-06-09 | 1977-12-16 | Shionogi & Co Ltd | Sugar coating on solid preparations |
US4163031A (en) * | 1977-10-25 | 1979-07-31 | Celanese Corporation | Powder composition and method of preparation |
DE2849494A1 (en) | 1978-11-15 | 1980-05-29 | Voss Gunter M | METHOD FOR THE PRODUCTION OF MEDICINAL FORMS |
US4548825A (en) | 1978-11-15 | 1985-10-22 | Boehringer Ingelheim Gmbh | Method for ink-jet printing on uncoated tablets or uncoated tablet cores |
CA1140784A (en) | 1979-06-04 | 1983-02-08 | Xerox Corporation | Conductive powder coated electrostatographic carriers |
GB2056885A (en) | 1979-08-08 | 1981-03-25 | Blundell Permoglaze Ltd | Powder coating cellulose fibre substrates |
US4543370A (en) * | 1979-11-29 | 1985-09-24 | Colorcon, Inc. | Dry edible film coating composition, method and coating form |
JPS5911563B2 (en) | 1980-02-27 | 1984-03-16 | 日本原子力研究所 | Method for manufacturing multilayer sustained release composites |
JPS57171428A (en) * | 1981-04-13 | 1982-10-22 | Sankyo Co Ltd | Preparation of coated solid preparation |
US4454125A (en) * | 1982-04-22 | 1984-06-12 | Demopoulos Harry B | Dry powder formulations having improved flow and compressibility characteristics, and method for the preparation thereof |
US4482387A (en) | 1982-07-12 | 1984-11-13 | E. R. Squibb & Sons, Inc. | Powdered wax, tablet coated therewith and method |
FR2534139B1 (en) | 1982-10-07 | 1986-08-29 | Laruelle Claude | NOVEL GALENIC FORM OF SULPIRIDE, METHOD FOR PREPARING SAME, AND MEDICINAL PRODUCT COMPRISING THIS NEW FORM |
US4704295A (en) | 1983-09-19 | 1987-11-03 | Colorcon, Inc. | Enteric film-coating compositions |
DE3478445D1 (en) | 1983-10-06 | 1989-07-06 | Kohjin Co | Process for preparing carboxymethyl ethyl cellulose suitable for enteric coating |
GB8414220D0 (en) | 1984-06-04 | 1984-07-11 | Sterwin Ag | Medicaments in unit dose form |
EP0212747B1 (en) | 1985-08-16 | 1991-04-10 | The Procter & Gamble Company | Drug particles having constant release and immediate release |
JPS62103012A (en) | 1985-10-23 | 1987-05-13 | Eisai Co Ltd | Multi-layered granule |
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
US4810501A (en) * | 1986-06-17 | 1989-03-07 | Warner-Lambert Company | Sustained release pharmaceutical preparations |
JPS6327424A (en) | 1986-07-17 | 1988-02-05 | Shionogi & Co Ltd | Sustained release pharmaceutical and production thereof |
FR2602423B1 (en) | 1986-08-08 | 1989-05-05 | Ethypharm Sa | PROCESS FOR THE PREPARATION OF A FENOFIBRATE-BASED MEDICINAL PRODUCT, OBTAINED BY THIS PROCESS |
DE3630603A1 (en) | 1986-09-09 | 1988-03-10 | Desitin Arzneimittel Gmbh | PHARMACEUTICAL AND DOSAGE FORM FOR MEDICINAL ACTIVE SUBSTANCES, REAGENTS OR THE LIKE, AND METHOD FOR THE PRODUCTION THEREOF |
US5026560A (en) | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
GB8707740D0 (en) | 1987-04-01 | 1987-05-07 | Strathclyde Minerals Ltd | Composition |
DE3721721C1 (en) * | 1987-07-01 | 1988-06-09 | Hoechst Ag | Process for coating granules |
DE8712547U1 (en) * | 1987-09-17 | 1987-11-19 | Behr-Industrieanlagen GmbH & Co, 7121 Ingersheim | Workpiece carrier for electrostatic workpiece coating |
US4988208A (en) * | 1987-10-08 | 1991-01-29 | Koshin Kenki Kogyo Co., Ltd. | Method of and apparatus for mixing or dispersing particles |
US4994273A (en) * | 1987-11-02 | 1991-02-19 | Merck & Co., Inc. | Solubility modulated drug delivery device |
DE3827214A1 (en) * | 1988-08-11 | 1990-02-15 | Roehm Gmbh | RETARDED MEDICAMENT AND METHOD FOR THE PRODUCTION THEREOF |
US5206030A (en) | 1990-02-26 | 1993-04-27 | Fmc Corporation | Film-forming composition and use for coating pharmaceuticals, foods and the like |
US5084287A (en) | 1990-03-15 | 1992-01-28 | Warner-Lambert Company | Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat |
EP0452862B1 (en) | 1990-04-18 | 1995-07-19 | Asahi Kasei Kogyo Kabushiki Kaisha | Spherical seed cores, spherical granules and process for production thereof |
GB9009390D0 (en) | 1990-04-26 | 1990-06-20 | Smith Kline French Lab | Pharmaceutical compositions |
ATE135729T1 (en) | 1990-06-01 | 1996-04-15 | Courtaulds Coatings Holdings | COLORED POWDER COATING COMPOSITIONS |
US5436026A (en) * | 1990-11-05 | 1995-07-25 | Mcneil-Ppc, Inc. | Discharge and transfer system for apparatus for gelatin coating tablets |
ATE192335T1 (en) * | 1990-12-20 | 2000-05-15 | Warner Jenkinson Co Inc | MOIST POWDER FILM-FORMING COMPOSITIONS |
GB2253164B (en) | 1991-02-22 | 1994-10-05 | Hoechst Uk Ltd | Improvements in or relating to electrostatic coating of substrates of medicinal products |
GB2256648B (en) * | 1991-05-29 | 1995-08-30 | Colorcon Ltd | Wax polish composition |
JP2711036B2 (en) | 1991-10-11 | 1998-02-10 | 日本ペイント株式会社 | Powder coatings and raw materials for powder coatings |
US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
JP3138838B2 (en) * | 1992-04-30 | 2001-02-26 | 東レ・ダウコーニング・シリコーン株式会社 | Manufacturing method of mixed powder |
PH30929A (en) | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
GB9223300D0 (en) | 1992-11-06 | 1992-12-23 | Courtaulds Coatings Holdings | Powder coating compositions and their use |
US5411730A (en) * | 1993-07-20 | 1995-05-02 | Research Corporation Technologies, Inc. | Magnetic microparticles |
CH686518A5 (en) * | 1993-10-05 | 1996-04-15 | Asahi Optical Co Ltd | Granular polymer composite manufacturing processes for this and diagnostic agents. |
IT1265473B1 (en) | 1993-12-30 | 1996-11-22 | Otefal Srl | PROCEDURE FOR THE PRODUCTION OF POWDERS WITH CONTROLLED GRANULOMETRY AND PRODUCT IN POWDER SO OBTAINED |
US5395626A (en) | 1994-03-23 | 1995-03-07 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
DE4414079A1 (en) | 1994-04-22 | 1995-10-26 | Basf Ag | Double-phase gas passivated metal pigments |
JP2913377B2 (en) | 1994-04-22 | 1999-06-28 | 株式会社巴川製紙所 | Powder paint |
AUPM695294A0 (en) | 1994-07-20 | 1994-08-11 | Borody, Thomas Julius | Improved combination therapy dose unit |
US5871751A (en) | 1994-10-12 | 1999-02-16 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Renibacterium salmoninarum vaccine and method for its preparation |
US5615614A (en) * | 1995-04-03 | 1997-04-01 | Van Pelt Equipment Corporation | Thermography process and apparatus |
ATE293440T1 (en) * | 1995-05-09 | 2005-05-15 | Phoqus Pharmaceuticals Ltd | POWDER COATING COMPOSITION FOR ELECTROSTATIC COATING OF PHARMACEUTICAL SUBSTRATES |
US5714007A (en) | 1995-06-06 | 1998-02-03 | David Sarnoff Research Center, Inc. | Apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate |
US5669973A (en) * | 1995-06-06 | 1997-09-23 | David Sarnoff Research Center, Inc. | Apparatus for electrostatically depositing and retaining materials upon a substrate |
US5642727A (en) * | 1995-07-25 | 1997-07-01 | David Sarnoff Research Center, Inc. | Inhaler apparatus using a tribo-electric charging technique |
US6026809A (en) | 1996-01-25 | 2000-02-22 | Microdose Technologies, Inc. | Inhalation device |
US5858099A (en) | 1996-04-09 | 1999-01-12 | Sarnoff Corporation | Electrostatic chucks and a particle deposition apparatus therefor |
US5753302A (en) * | 1996-04-09 | 1998-05-19 | David Sarnoff Research Center, Inc. | Acoustic dispenser |
US5846595A (en) * | 1996-04-09 | 1998-12-08 | Sarnoff Corporation | Method of making pharmaceutical using electrostatic chuck |
US5788814A (en) | 1996-04-09 | 1998-08-04 | David Sarnoff Research Center | Chucks and methods for positioning multiple objects on a substrate |
NZ332962A (en) | 1996-06-10 | 2000-08-25 | Delsys Pharmaceutical Corp | Inhaler apparatus with modified surfaces for enhanced release of dry powders that are electrostatically charged |
US5871010A (en) | 1996-06-10 | 1999-02-16 | Sarnoff Corporation | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
US5857456A (en) | 1996-06-10 | 1999-01-12 | Sarnoff Corporation | Inhaler apparatus with an electronic means for enhanced release of dry powders |
US5699649A (en) * | 1996-07-02 | 1997-12-23 | Abrams; Andrew L. | Metering and packaging device for dry powders |
GB9623634D0 (en) * | 1996-11-13 | 1997-01-08 | Bpsi Holdings Inc | Method and apparatus for the coating of substrates for pharmaceutical use |
US5792513A (en) * | 1997-03-07 | 1998-08-11 | Koslow Technologies Corporation | Continuous solid state web coating process |
US6045753A (en) | 1997-07-29 | 2000-04-04 | Sarnoff Corporation | Deposited reagents for chemical processes |
US6004752A (en) | 1997-07-29 | 1999-12-21 | Sarnoff Corporation | Solid support with attached molecules |
US6237590B1 (en) | 1997-09-18 | 2001-05-29 | Delsys Pharmaceutical Corporation | Dry powder delivery system apparatus |
-
1996
- 1996-05-08 AT AT96913629T patent/ATE293440T1/en not_active IP Right Cessation
- 1996-05-08 DE DE69634631T patent/DE69634631T2/en not_active Expired - Lifetime
- 1996-05-08 AT AT96913630T patent/ATE233604T1/en not_active IP Right Cessation
- 1996-05-08 TR TR97/01324T patent/TR199701324T1/en unknown
- 1996-05-08 JP JP8533866A patent/JPH11507292A/en active Pending
- 1996-05-08 CA CA002220506A patent/CA2220506C/en not_active Expired - Fee Related
- 1996-05-08 AU AU56551/96A patent/AU5655196A/en not_active Abandoned
- 1996-05-08 EP EP96913629A patent/EP0824344B1/en not_active Expired - Lifetime
- 1996-05-08 PL PL96323315A patent/PL323315A1/en unknown
- 1996-05-08 WO PCT/GB1996/001102 patent/WO1996035516A1/en active IP Right Grant
- 1996-05-08 ES ES96913630T patent/ES2194100T3/en not_active Expired - Lifetime
- 1996-05-08 DK DK96913629T patent/DK0824344T3/en active
- 1996-05-08 AU AU56552/96A patent/AU5655296A/en not_active Abandoned
- 1996-05-08 PL PL96323314A patent/PL323314A1/en unknown
- 1996-05-08 CN CN96193771A patent/CN1183738A/en active Pending
- 1996-05-08 ES ES96913629T patent/ES2240994T3/en not_active Expired - Lifetime
- 1996-05-08 TR TR97/01323T patent/TR199701323T1/en unknown
- 1996-05-08 EP EP96913630A patent/EP0869847B1/en not_active Expired - Lifetime
- 1996-05-08 PT PT96913629T patent/PT824344E/en unknown
- 1996-05-08 DE DE69626545T patent/DE69626545T2/en not_active Expired - Lifetime
- 1996-05-08 BR BR9608208-9A patent/BR9608208A/en not_active Application Discontinuation
- 1996-05-08 CZ CZ973521A patent/CZ352197A3/en unknown
- 1996-05-08 DK DK96913630T patent/DK0869847T3/en active
- 1996-05-08 BR BR9608209-7A patent/BR9608209A/en unknown
- 1996-05-08 WO PCT/GB1996/001101 patent/WO1996035413A1/en active IP Right Grant
- 1996-05-08 CZ CZ973520A patent/CZ352097A3/en unknown
- 1996-05-08 KR KR1019970707961A patent/KR19990008431A/en not_active Application Discontinuation
- 1996-05-08 HU HU9901981A patent/HUP9901981A3/en unknown
- 1996-05-08 CN CN96193804A patent/CN1183715A/en active Pending
- 1996-05-08 PT PT96913630T patent/PT869847E/en unknown
- 1996-05-08 EP EP00117256A patent/EP1075838A3/en not_active Ceased
- 1996-05-08 JP JP53386596A patent/JP4137998B2/en not_active Expired - Fee Related
- 1996-05-08 KR KR1019970707960A patent/KR19990008430A/en not_active Application Discontinuation
-
1997
- 1997-11-07 NO NO975132A patent/NO975132L/en unknown
- 1997-11-07 NO NO975131A patent/NO975131L/en unknown
- 1997-11-10 US US08/966,582 patent/US6406738B1/en not_active Expired - Fee Related
- 1997-11-10 US US08/999,564 patent/US6117479A/en not_active Expired - Lifetime
-
2001
- 2001-08-28 US US09/939,631 patent/US20020034592A1/en not_active Abandoned
-
2003
- 2003-12-19 US US10/739,943 patent/US7070656B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08244678A (en) * | 1995-03-10 | 1996-09-24 | Shinkurushima Dock:Kk | Tank barge type liquid cargo transport ship |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4137998B2 (en) | Powder coating composition for electrostatic coating of pharmaceutical substrates | |
US7008668B2 (en) | Powder coating composition for electrostatic coating of pharmaceutical substrates | |
US7862848B2 (en) | Direct coating solid dosage forms using powdered materials | |
Qiao et al. | A novel electrostatic dry powder coating process for pharmaceutical dosage forms: Immediate release coatings for tablets | |
Luo et al. | Dry coating, a novel coating technology for solid pharmaceutical dosage forms | |
Yang et al. | An update on electrostatic powder coating for pharmaceuticals | |
GB2333975A (en) | Electrostatic coating with powder material | |
ZA200509709B (en) | Production of capsule shells and capsules | |
JP3471977B2 (en) | Enteric preparations coated with solvent-free enteric coatings using liquid plasticizers | |
Albertini et al. | A novel approach for dry powder coating of pellets with Ethylcellulose. Part I: Evaluation of film formulation and process set up | |
Saikh | Coating processes of pharmaceutical applicability: a glimpse | |
MXPA97008614A (en) | Composition of powder coating for the electrostatic coating of farmaceuti substrates | |
Zhu et al. | Dry Powder Coating of Pharmaceutical Solid Dosages | |
JP3628401B2 (en) | Enteric preparation with solvent-free enteric coating | |
AU2005315376A1 (en) | Formulations for production of capsule shells and capsules | |
Kumar et al. | Mucoadhesive microencapsulation: a new tool in drug delivery systems | |
JPH04202124A (en) | Production of formulation controlling release of medicinal ingredient by spray-drying granulation method | |
Yang | Powder Coating for Pharmaceutical Solid Dosage Forms | |
JPH08333240A (en) | Enteric coated preparation coated with solventless enteric coating agent using powdery or pellet wax |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070306 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070606 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070627 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070723 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070813 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070803 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070910 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070906 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080303 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080501 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080520 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080605 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110613 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110613 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110613 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110613 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120613 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120613 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130613 Year of fee payment: 5 |
|
LAPS | Cancellation because of no payment of annual fees |